Amyloid	B
beta	O
protein	O
disruption	O
of	O
cholinergic	O
and	O
growth	O
factor	O
phospholipase	B
C	I
signals	O
could	O
underlie	O
cognitive	O
and	O
neurodegerative	O
aspects	O
of	O
Alzheimer	O
's	O
disease	O

If	O
daily	O
oxytocin	B
injections	O
are	O
repeated	O
over	O
a	O
5-day	O
period	O
,	O
blood	O
pressure	O
is	O
decreased	O
by	O
10	O
-	O
20	O
mmHg	O
,	O
the	O
withdrawal	O
latency	O
to	O
heat	O
stimuli	O
is	O
prolonged	O
,	O
cortisol	O
levels	O
are	O
decreased	O
and	O
insulin	B
and	O
cholecystokinin	O
levels	O
are	O
increased	O

Constitutive	O
expression	O
of	O
PKABA1	O
drastically	O
suppressed	O
expression	O
of	O
low-	O
and	O
high	O
-	O
pI	O
alpha	B
-	I
amylase	I
and	O
protease	O
genes	O
induced	O
by	O
GA	B

The	O
bovine	O
ovarian	O
granulosa	O
cell	O
model	O
is	O
a	O
primary	O
culture	O
system	O
where	O
under	O
stimulation	O
by	O
insulin	B
or	O
IGF	O
-	O
I	O
and	O
LH	O
the	O
endogenous	O
oxytocin	B
gene	O
is	O
massively	O
upregulated	O

In	O
addition	O
,	O
abscisic	O
acid	O
-	O
mediated	O
inhibition	O
of	O
gibberellin	B
-	O
stimulated	O
responses	O
seems	O
to	O
depend	O
on	O
the	O
activation	O
of	O
a	O
phospholipase	O
D	O
during	O
induction	O
of	O
alpha	B
-	I
amylase	I
in	O
barley	O
aleurone	O
cells	O
as	O
well	O
as	O
on	O
a	O
putative	O
acetyltransferase	O
involved	O
in	O
elongation	O
growth	O
.	O

The	O
deduced	O
consensus	O
closely	O
resembled	O
gibberellin	B
response	O
elements	O
in	O
alpha	B
-	I
amylase	I
promoters	O

Molecular	O
characterization	O
of	O
catalytic	O
-	O
subunit	O
cDNA	O
sequences	O
encoding	O
protein	O
phosphatases	O
1	O
and	O
2A	O
and	O
study	O
of	O
their	O
roles	O
in	O
the	O
gibberellin	B
-	O
dependent	O
Osamy	B
-	I
c	I
expression	O
in	O
rice	O

To	O
understand	O
the	O
molecular	O
mechanism	O
of	O
gibberellin	B
-	O
dependent	O
gene	O
regulation	O
,	O
the	O
effect	O
of	O
three	O
phosphatase	O
inhibitors	O
on	O
the	O
germination	O
of	O
rice	O
seeds	O
and	O
the	O
expression	O
of	O
a	O
target	O
gene	O
,	O
the	O
alpha	B
-	I
amylase	I
gene	O
,	O
Osamy	O
-	O
c	O
,	O
were	O
measured	O

To	O
further	O
understand	O
the	O
possible	O
role	O
of	O
protein	O
phosphatases	O
1	O
and	O
2A	O
in	O
the	O
GA	B
-	O
dependent	O
expression	O
of	O
Osamy	B
-	I
c	I
,	O
we	O
isolated	O
cDNA	O
clones	O
encoding	O
protein	O
phosphatase	O
1	O
and	O
protein	O
phosphatase	O
2A	O
from	O
a	O
rice	O
aleurone	O
cDNA	O
library	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
protein	O
phosphatases	O
PP1	O
or	O
PP2A	O
are	O
involved	O
in	O
the	O
GA	B
-	O
dependent	O
expression	O
of	O
the	O
rice	O
Osamy	B
-	I
c	I
gene	O
,	O
though	O
the	O
PP1	O
or	O
/	O
and	O
PP2A	O
enzymatic	O
activities	O
as	O
well	O
as	O
mRNA	O
levels	O
do	O
not	O
increase	O
upon	O
GA3	O
treatment	O

Fasting	O
and	O
leptin	B
modulate	O
adipose	O
and	O
muscle	O
uncoupling	B
protein	I
:	O
divergent	O
effects	O
between	O
messenger	O
ribonucleic	O
acid	O
and	O
protein	O
expression	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
effects	O
of	O
fasting	O
for	O
2	O
days	O
and	O
exogenous	O
s.c	O
.	O
leptin	B
,	O
200	O
microg	O
every	O
8	O
h	O
for	O
2	O
days	O
,	O
on	O
the	O
regulation	O
of	O
uncoupling	B
protein	I
(	O
UCP	O
)	O
subtypes	O
in	O
brown	O
adipose	O
tissue	O
(	O
BAT	O
)	O
and	O
gastrocnemius	O
muscle	O

Leptin	B
,	O
compared	O
with	O
vehicle	O
,	O
did	O
not	O
alter	O
BAT	O
UCP-1	B
or	O
UCP-3	B
mRNA	O
or	O
protein	O
expression	O
when	O
administered	O
to	O
normal	O
ad	O
libitum	O
fed	O
rats	O

Fasting	O
significantly	O
decreased	O
BAT	O
UCP-1	B
and	O
UCP-3	B
mRNA	O
expression	O
,	O
to	O
31	O
%	O
and	O
30	O
%	O
of	O
ad	O
libitum	O
fed	O
controls	O
,	O
respectively	O
,	O
effects	O
which	O
were	O
prevented	O
by	O
administration	O
of	O
leptin	B
to	O
fasted	O
rats	O

Fasting	O
also	O
significantly	O
decreased	O
BAT	O
UCP-1	B
protein	O
expression	O
,	O
to	O
67	O
%	O
of	O
control	O
;	O
however	O
,	O
that	O
effect	O
was	O
not	O
prevented	O
by	O
leptin	B
treatment	O

Fasting	O
,	O
with	O
or	O
without	O
leptin	B
administration	O
,	O
did	O
not	O
affect	O
BAT	O
UCP-2	B
mRNA	O
;	O
however	O
,	O
leptin	B
administration	O
to	O
ad	O
libitum	O
fed	O
rats	O
significantly	O
increased	O
BAT	O
UCP-2	B
mRNA	O
,	O
to	O
138	O
%	O
of	O
control	O

Fasting	O
significantly	O
enhanced	O
gastrocnemius	O
muscle	O
UCP-3	B
mRNA	O
(	O
411	O
%	O
of	O
control	O
)	O
and	O
protein	O
expression	O
(	O
168	O
%	O
of	O
control	O
)	O
,	O
whereas	O
leptin	B
administration	O
to	O
fasted	O
rats	O
did	O
not	O
alter	O
either	O
of	O
these	O
effects	O

In	O
summary	O
,	O
UCP	B
subtype	O
mRNA	O
and	O
protein	O
are	O
regulated	O
in	O
tissue-	O
and	O
subtype	O
-	O
specific	O
fashion	O
by	O
leptin	B
and	O
food	O
restriction	O

Amyloid	B
beta	O
protein	O
(	O
25	O
-	O
35	O
)	O
stimulation	O
of	O
phospholipases	B
A	O
,	O
C	O
and	O
D	O
activities	O
of	O
LA	O
-	O
N-2	O
cells	O

[	O
3H	O
]	O
Inositol	O
prelabeled	O
LA	O
-	O
N-2	O
cells	O
were	O
exposed	O
to	O
varying	O
concentrations	O
of	O
A	B
beta	I
P	I
,	O
from	O
20	O
to	O
125	O
micrograms	O
/	O
ml	O
,	O
and	O
phospholipase	B
C	I
activation	O
was	O
measured	O

The	O
effects	O
of	O
adrenergic	O
,	O
metabotropic	O
amino	O
acid	O
and	O
bombesin	O
antagonists	O
on	O
the	O
A	B
beta	I
P	I
mediated	O
stimulation	O
of	O
phospholipase	B
C	I
activity	O
was	O
investigated	O

Propranolol	O
,	O
a	O
beta	O
adrenergic	O
antagonist	O
,	O
7-chloro	O
-	O
kynurenic	O
acid	O
,	O
a	O
metabotropic	O
amino	O
acid	O
antagonist	O
,	O
and	O
[	O
Tyr4-D	O
-	O
Phe12	O
]	O
bombesin	O
,	O
a	O
bombesin	O
antagonist	O
,	O
blunted	O
the	O
A	B
beta	I
P	I
stimulation	O
of	O
phospholipase	B
C	I
activity	O
in	O
[	O
3H	O
]	O
inositol	O
prelabeled	O
LA	O
-	O
N-2	O
cells	O

This	O
suggests	O
that	O
amyloid	B
beta	O
protein	O
activation	O
of	O
phospholipase	B
C	I
may	O
be	O
receptor	O
mediated	O

The	O
phospholipase	B
C	I
inhibitor	O
U	O
71322	O
prevented	O
the	O
activation	O
of	O
phospholipase	B
C	I
by	O
A	B
beta	I
P	I

Analyses	O
of	O
hormone	O
regulation	O
of	O
expression	O
of	O
mRNA	O
for	O
the	O
aleurone	O
RNase	O
revealed	O
that	O
,	O
like	O
the	O
pattern	O
for	O
alpha	B
-	I
amylase	I
,	O
mRNA	O
levels	O
increased	O
in	O
the	O
presence	O
of	O
gibberellic	B
acid	I
,	O
and	O
its	O
antagonist	O
abscisic	O
acid	O
prevented	O
this	O
effect	O

Quantitative	O
studies	O
at	O
early	O
times	O
demonstrated	O
that	O
cycloheximide	O
treatment	O
of	O
aleurone	O
layers	O
increased	O
mRNA	O
levels	O
4-fold	O
,	O
whereas	O
a	O
combination	O
of	O
gibberellin	B
plus	O
cycloheximide	O
treatment	O
was	O
required	O
to	O
increase	O
alpha	B
-	I
amylase	I
mRNA	O
levels	O
to	O
the	O
same	O
extent	O

The	O
experiments	O
were	O
concluded	O
by	O
taking	O
blood	O
samples	O
for	O
later	O
analysis	O
of	O
plasma	O
glucose	O
and	O
plasma	O
levels	O
of	O
the	O
following	O
hormones	O
:	O
insulin	B
,	O
gastrin	O
,	O
CCK	O
,	O
glucagon	O
,	O
somatostatin	O
,	O
oxytocin	B
and	O
corticosterone	O

The	O
low	O
-	O
performing	O
Stock	O
B	O
animals	O
were	O
characterized	O
by	O
[	O
1	O
]	O
being	O
more	O
reactive	O
to	O
sensory	O
stimulation	O
:	O
higher	O
startle	O
amplitude	O
and	O
shorter	O
startle	O
latency	O
;	O
[	O
2	O
]	O
having	O
higher	O
plasma	O
insulin	B
and	O
corticosterone	O
levels	O
,	O
whereas	O
plasma	O
gastrin	O
and	O
oxytocin	B
were	O
significantly	O
lowered	O
and	O
a	O
strong	O
tendency	O
for	O
a	O
decrease	O
also	O
in	O
plasma	O
CCK	O

In	O
normal	O
pancreatic	O
islets	O
,	O
UCP-2	B
is	O
upregulated	O
by	O
leptin	B
and	O
is	O
low	O
in	O
leptin	B
-	O
resistant	O
islets	O
of	O
ZDF	O
rats	O

To	O
determine	O
whether	O
UCP-2	B
does	O
,	O
in	O
fact	O
,	O
have	O
uncoupling	O
activity	O
and	O
,	O
if	O
so	O
,	O
whether	O
such	O
activity	O
would	O
favorably	O
influence	O
the	O
abnormalities	O
in	O
leptin	B
-	O
unresponsive	O
UCP-2-underexpressing	B
islets	O
of	O
diabetic	O
ZDF	O
rats	O
,	O
we	O
transferred	O
the	O
UCP-2	B
gene	O
to	O
the	O
islets	O
of	O
diabetic	O
ZDF	O
rats	O
and	O
lean	O
(	O
+	O
/+	O
)	O
ZDF	O
control	O
rats	O

We	O
conclude	O
that	O
UCP-2	B
has	O
uncoupling	O
function	O
when	O
overexpressed	O
in	O
leptin	B
-	O
insensitive	O
islets	O
and	O
that	O
its	O
overexpression	O
corrects	O
the	O
underexpression	O
of	O
the	O
insulin	O
gene	O
and	O
ameliorates	O
glucose	O
-	O
stimulated	O
insulin	O
secretion	O
,	O
possibly	O
by	O
increasing	O
the	O
ATP	O
:	O
ADP	O
ratio	O

Overexpression	O
of	O
G11alpha	O
and	O
isoforms	O
of	O
phospholipase	B
C	I
in	O
islet	O
beta	O
-	O
cells	O
reveals	O
a	O
lack	O
of	O
correlation	O
between	O
inositol	O
phosphate	O
accumulation	O
and	O
insulin	B
secretion	O
.	O

It	O
has	O
been	O
suggested	O
that	O
insulin	B
secretion	O
from	O
pancreatic	O
islets	O
may	O
be	O
mediated	O
in	O
part	O
by	O
activation	O
of	O
phospholipases	B
C	I
(	O
PLCs	O
)	O
and	O
phosphoinositide	O
hydrolysis	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
relatively	O
modest	O
fuel	O
-	O
stimulated	O
insulin	B
secretion	O
responses	O
of	O
rodent	O
beta	O
-	O
cell	O
lines	O
might	O
be	O
explained	O
by	O
inadequate	O
expression	O
or	O
activation	O
of	O
PLC	B
isoforms	O
.	O

Adenovirus	O
-	O
mediated	O
overexpression	O
of	O
PLC	B
-	O
delta1	O
,	O
-beta1	O
,	O
or	O
-beta3	O
in	O
INS-1	O
or	O
betaG	O
40	O
/	O
110	O
cells	O
results	O
in	O
little	O
or	O
no	O
enhancement	O
in	O
inositol	O
phosphate	O
(	O
IP	O
)	O
accumulation	O
and	O
no	O
improvement	O
in	O
insulin	B
secretion	O
when	O
the	O
cells	O
are	O
stimulated	O
with	O
glucose	O
or	O
carbachol	O
,	O
despite	O
the	O
fact	O
that	O
the	O
overexpressed	O
proteins	O
are	O
fully	O
active	O
in	O
cell	O
extracts	O
.	O

Overexpression	O
of	O
PLC	B
-	O
beta1	O
or	O
-beta3	O
in	O
normal	O
rat	O
islets	O
elicits	O
a	O
larger	O
increase	O
in	O
IP	O
accumulation	O
but	O
,	O
again	O
,	O
has	O
no	O
effect	O
on	O
insulin	B
secretion	O
.	O

Because	O
the	O
effect	O
of	O
carbachol	O
on	O
insulin	B
secretion	O
is	O
thought	O
to	O
be	O
mediated	O
through	O
muscarinic	O
receptors	O
that	O
link	O
to	O
the	O
Gq	O
/	O
11	O
class	O
of	O
heterotrimeric	O
G	O
proteins	O
,	O
we	O
also	O
overexpressed	O
G11alpha	O
in	O
INS-1	O
cells	O
,	O
either	O
alone	O
or	O
in	O
concert	O
with	O
overexpression	O
of	O
PLC	B
-	O
beta1	O
or	O
-beta3	O
.	O

Overexpression	O
of	O
G11alpha	O
enhances	O
IP	O
accumulation	O
,	O
an	O
effect	O
slightly	O
potentiated	O
by	O
co	O
-	O
overexpression	O
of	O
PLC	B
-	O
beta1	O
or	O
-beta3	O
,	O
but	O
these	O
maneuvers	O
do	O
not	O
affect	O
glucose	O
or	O
carbachol	O
-	O
stimulated	O
insulin	B
secretion	O
.	O

Furthermore	O
,	O
our	O
14C	O
-	O
acetate	O
-	O
labeling	O
studies	O
showed	O
a	O
50	O
%	O
reduction	O
in	O
cholesteryl	B
ester	I
synthesis	O
in	O
the	O
presence	O
of	O
either	O
flavonoid	B
,	O
which	O
could	O
account	O
for	O
the	O
reduction	O
in	O
net	O
apoB	O
secretion	O
caused	O
by	O
incubation	O
with	O
these	O
compounds	O

An	O
inhibitor	O
of	O
PKC	B
,	O
Ro31	O
-	O
8220	O
(	O
10	O
microM	O
)	O
,	O
abolished	O
the	O
ability	O
of	O
PDBu	O
to	O
decrease	O
[	O
Ca	O
(	O
2+	O
)	O
]	O
(	O
i	O
)	O
,	O
without	O
affecting	O
the	O
response	O
to	O
maximal	O
or	O
submaximal	O
concentrations	O
of	O
AVP	B

The	O
expression	O
of	O
uterine	O
UCP2	B
and	O
UCP3	B
were	O
up	O
-	O
regulated	O
by	O
3.2-	O
and	O
1.5-fold	O
,	O
respectively	O
,	O
during	O
the	O
late	O
stage	O
of	O
pregnancy	O
with	O
an	O
increase	O
of	O
WAT	O
leptin	B
mRNA	O
expression	O
and	O
exogenous	O
administration	O
of	O
leptin	B
resulted	O
in	O
induction	O
of	O
the	O
uterine	O
UCP2	B
and	O
UCP3	B
levels	O

These	O
results	O
indicate	O
that	O
UCP	B
gene	O
expressions	O
during	O
pregnancy	O
are	O
regulated	O
tissue	O
-	O
dependently	O
,	O
and	O
up	O
-	O
regulation	O
of	O
uterine	O
UCP2	B
and	O
UCP3	B
mRNA	O
may	O
be	O
due	O
to	O
increased	O
leptin	B
levels	O

PI	B
-	I
PLC	I
treatment	O
of	O
fetal	O
guinea	O
pig	O
brain	O
cultures	O
substantially	O
reduced	O
the	O
amount	O
of	O
Abeta40	B
and	O
Abeta42	B
in	O
the	O
medium	O
but	O
had	O
no	O
effect	O
on	O
sAPPalpha	O

When	O
this	O
parental	O
line	O
was	O
treated	O
with	O
PI	B
-	I
PLC	I
,	O
Abeta40	B
,	O
Abeta42	B
,	O
and	O
sAPPbeta	O
decreased	O
to	O
levels	O
similar	O
to	O
those	O
observed	O
in	O
the	O
mutant	O
line	O
,	O
and	O
the	O
mutant	O
line	O
was	O
resistant	O
to	O
these	O
effects	O
of	O
PI	B
-	I
PLC	I

A	O
neurotoxic	O
fragment	O
of	O
amyloid	B
,	O
Abeta	O
25	O
-	O
35	O
,	O
incubated	O
in	O
the	O
presence	O
of	O
endogenous	O
Ca2	O
+	O
,	O
increased	O
significantly	O
the	O
PI	B
-	I
PLC	I
activity	O
of	O
normoxic	O
brain	O

In	O
its	O
non	O
-	O
aggregated	O
form	O
,	O
Abeta	B
25	I
-	I
35	I
activates	O
PI	B
-	I
PLC	I
but	O
in	O
the	O
aggregated	O
form	O
the	O
enzymatic	O
activity	O
decreased	O

Thus	O
,	O
Abeta	B
25	I
-	I
35	I
exerts	O
a	O
similar	O
effect	O
on	O
the	O
membrane	O
-	O
bound	O
PI	B
-	I
PLC	I
from	O
normoxic	O
brain	O
or	O
subjected	O
to	O
ischemia	O
reperfusion	O
injury	O

Ischemia	O
-	O
reperfusion	O
injury	O
had	O
no	O
effect	O
on	O
Abeta	B
-	O
evoked	O
alterations	O
of	O
synaptic	O
plasma	O
membrane	O
-	O
bound	O
PI	B
-	I
PLC	I

Sympathetic	O
inhibition	O
,	O
leptin	B
,	O
and	O
uncoupling	B
protein	I
subtype	O
expression	O
in	O
normal	O
fasting	O
rats	O

To	O
further	O
investigate	O
neural	O
effects	O
on	O
leptin	B
and	O
uncoupling	B
proteins	I
(	O
UCPs	O
)	O
,	O
we	O
studied	O
in	O
vivo	O
perturbations	O
intended	O
to	O
block	O
adrenergic	O
input	O
to	O
peripheral	O
tissues	O

We	O
examined	O
plasma	O
leptin	B
,	O
leptin	B
mRNA	O
,	O
and	O
adipose	O
and	O
muscle	O
UCP	B
subtype	O
mRNA	O
in	O
rats	O
treated	O
with	O
alpha	O
-	O
methyl	O
-	O
p	O
-	O
tyrosine	O
methyl	O
ester	O
(	O
AMPT	O
-	O
ME	O
)	O
,	O
which	O
inhibits	O
catecholamine	O
synthesis	O
and	O
6-hydroxydopamine	O
(	O
6HDA	O
)	O
,	O
which	O
is	O
toxic	O
to	O
catecholinergic	O
nerve	O
terminals	O
but	O
,	O
unlike	O
AMPT	O
-	O
ME	O
,	O
does	O
not	O
enter	O
the	O
central	O
nervous	O
system	O

Intraperitoneal	O
6HDA	O
,	O
100	O
mg	O
/	O
kg	O
,	O
as	O
a	O
single	O
dose	O
at	O
1800	O
,	O
increased	O
plasma	O
leptin	B
approximately	O
twofold	O
after	O
18	O
-	O
20	O
h	O
,	O
increased	O
IBAT	O
(	O
but	O
not	O
epididymal	O
fat	O
)	O
leptin	B
mRNA	O
by	O
two-	O
to	O
threefold	O
,	O
and	O
decreased	O
IBAT	O
UCP-3	B
mRNA	O
to	O
30	O
-	O
40	O
%	O
of	O
control	O

However	O
,	O
the	O
in	O
vivo	O
modulation	O
of	O
leptin	B
and	O
UCPs	B
appears	O
complex	O
and	O
,	O
beyond	O
a	O
causal	O
effect	O
of	O
SNA	O
per	O
se	O
,	O
may	O
depend	O
on	O
concurrent	O
changes	O
in	O
plasma	O
insulin	O
,	O
glucose	O
,	O
and	O
circulatory	O
hemodynamics	O

Amyloid	B
beta	O
peptide	O
25	O
-	O
35	O
modulates	O
hydrolysis	O
of	O
phosphoinositides	O
by	O
membrane	O
phospholipase	B
(	I
s	I
)	I
C	I
of	O
adult	O
brain	O
cortex	O

Fresh	O
-	O
water	O
-	O
soluble	O
A	B
beta	I
25	O
-	O
35	O
activated	O
PI	B
-	I
PLC	I
in	O
SPM	O
markedly	O
by	O
two-	O
to	O
threefold	O
,	O
but	O
this	O
effect	O
was	O
absent	O
in	O
the	O
presence	O
of	O
2	O
mM	O
CaCl2	O

Moreover	O
,	O
A	B
beta	I
25	O
-	O
35	O
had	O
no	O
effect	O
on	O
basal	O
PIP2-PLC	B
activity	O
and	O
cytosolic	O
PI	B
-	I
PLC	I
and	O
PIP2-PLC	B

The	O
aggregated	O
form	O
of	O
A	B
beta	I
25	O
-	O
35	O
significantly	O
inhibited	O
PIP2-PLC	B
only	O
in	O
the	O
presence	O
of	O
endogenous	O
CaCl2	O

Vasopressin	B
stimulates	O
tyrosine	O
phosphorylation	O
by	O
activation	O
of	O
PKC	B
in	O
the	O
rat	O
smooth	O
muscle	O
cell	O
line	O
,	O
A-10	O

The	O
protein	B
kinase	I
C	I
(	O
PKC	O
)	O
inhibitors	O
:	O
staurosporine	O
,	O
H7	O
and	O
GF109203X	O
are	O
able	O
to	O
block	O
the	O
AVP	B
-	O
stimulated	O
phosphorylation	O

These	O
results	O
indicate	O
that	O
PKC	B
is	O
upstream	O
of	O
the	O
phosphorylation	O
,	O
a	O
motion	O
which	O
is	O
supported	O
by	O
the	O
fact	O
that	O
the	O
AVP	B
-	O
stimulated	O
phosphorylation	O
was	O
downregulated	O
by	O
phorbol	O
esters	O

The	O
effects	O
of	O
the	O
fluorinated	O
analogues	O
were	O
evaluated	O
on	O
inhibition	O
of	O
cress	O
seed	O
germination	O
and	O
inhibition	O
of	O
gibberellin	B
-	O
inducible	O
alpha	B
-	I
amylase	I
induction	O
in	O
embryoless	O
barley	O
half	O
-	O
seeds	O

(	O
2E	O
,	O
4E	O
)	O
-2-Fluoro-5-	O
(	O
1'-hydroxy-2',6	O
'	O
,	O
6'-trimethyl-2'-cyclohexen-1'-yl	O
)	O
-3-methyl-2,4-pentadienoic	O
acid	O
(	O
5b	O
)	O
showed	O
potent	O
inhibitory	O
activity	O
at	O
the	O
same	O
level	O
as	O
ABA	O
in	O
the	O
cress	O
seed	O
germination	O
test	O
,	O
and	O
5b	O
also	O
inhibited	O
gibberellin	B
-	O
inducible	O
alpha	B
-	I
amylase	I
induction	O
at	O
4	O
x	O
10	O
(	O
-	O
)	O
(	O
6	O
)	O
,	O
3	O
times	O
the	O
concentration	O
of	O
ABA	O
(	O
1	O
x	O
10	O
(	O
-	O
)	O
(	O
6	O
)	O
)	O
for	O
50	O
%	O
inhibition	O
of	O
alpha	B
-	I
amylase	I
production	O

These	O
results	O
suggest	O
that	O
,	O
in	O
isolated	O
white	O
adipocytes	O
,	O
the	O
released	O
adenosine	O
acts	O
as	O
a	O
helper	O
and/or	O
a	O
positive	O
regulator	O
for	O
insulin	B
in	O
the	O
release	O
of	O
leptin	O
via	O
an	O
activation	O
of	O
adenosine	O
A1	O
receptors	O
that	O
involves	O
the	O
PLC	B
-	O
PKC	O
pathway	O
.	O

The	O
etiology	O
for	O
diabetes	O
mellitus	O
in	O
PWS	O
may	O
be	O
related	O
to	O
the	O
morbid	O
obesity	O
and	O
consequent	O
insulin	B
resistance	O
,	O
because	O
a	O
decrease	O
of	O
oxytocin	B
neurons	O
and	O
leptin	O
resistance	O
in	O
PWS	O
may	O
cause	O
hyperphagia	O
,	O
inducing	O
obesity	O

We	O
previously	O
showed	O
that	O
arginine	B
vasopressin	I
(	O
AVP	O
)	O
stimulates	O
heat	O
shock	O
protein	O
27	O
(	O
HSP27	O
)	O
induction	O
through	O
protein	B
kinase	I
C	I
activation	O
in	O
aortic	O
smooth	O
muscle	O
A10	O
cells	O

Calphostin	O
C	O
and	O
ET-18-OCH	O
(	O
3	O
)	O
,	O
inhibitors	O
of	O
protein	B
kinase	I
C	I
,	O
reduced	O
the	O
phosphorylation	O
of	O
p38	O
MAP	O
kinase	O
by	O
AVP	B

Insulin	B
-	O
like	O
signaling	O
in	O
yeast	O
:	O
modulation	O
of	O
protein	O
phosphatase	O
2A	O
,	O
protein	O
kinase	O
A	O
,	O
cAMP	O
-	O
specific	O
phosphodiesterase	O
,	O
and	O
glycosyl	O
-	O
phosphatidylinositol	O
-	O
specific	O
phospholipase	B
C	I
activities	O

In	O
addition	O
,	O
glycosyl	B
-	I
phosphatidylinositol	I
-	I
specific	I
phospholipase	I
C	I
(	O
GPI	O
-	O
PLC	O
)	O
,	O
which	O
in	O
isolated	O
rat	O
adipocytes	O
is	O
activated	O
by	O
insulin	B
,	O
was	O
stimulated	O
to	O
up	O
to	O
5-fold	O
by	O
glucose	O
and	O
10-fold	O
by	O
glucose	O
plus	O
insulin	B
in	O
both	O
yeast	O
spheroplasts	O
and	O
intact	O
cells	O
leading	O
to	O
a	O
concentration	O
-	O
dependent	O
leftward	O
shift	O
of	O
the	O
glucose	O
-	O
response	O
curve	O
for	O
activation	O
of	O
the	O
GPI	B
-	I
PLC	I

GPI	B
-	I
PLC	I
was	O
most	O
pronouncedly	O
stimulated	O
by	O
authentic	O
human	O
insulin	B
compared	O
to	O
various	O
insulin	O
analogues	O
and	O
insulin	O
-	O
like	O
growth	O
factor	O
I	O

As	O
the	O
GPI	B
-	I
PLC	I
reaction	O
is	O
rate	O
limiting	O
,	O
the	O
efficiency	O
of	O
the	O
two	O
-	O
step	O
anchor	O
cleavage	O
was	O
significantly	O
increased	O
when	O
insulin	B
was	O
present	O
together	O
with	O
glucose	O
as	O
compared	O
to	O
glucose	O
alone	O

The	O
insulin	B
concentrations	O
effective	O
in	O
modulating	O
PP2A	O
,	O
PKA	O
,	O
cAMP	O
-	O
PDE	O
,	O
and	O
GPI	B
-	I
PLC	I
activities	O
correlate	O
well	O
with	O
those	O
required	O
for	O
half	O
-	O
saturation	O
of	O
the	O
specific	O
binding	O
sites	O
as	O
well	O
as	O
for	O
stimulation	O
of	O
protein	O
phosphorylation	O
and	O
glycogen	O
accumulation	O

The	O
data	O
suggest	O
that	O
mammalian	O
insulin	B
-	O
sensitive	O
cells	O
and	O
yeast	O
share	O
(	O
part	O
of	O
)	O
the	O
key	O
regulatory	O
mechanism	O
(	O
consisting	O
of	O
PP2A	O
,	O
PKA	O
,	O
cAMP	O
-	O
PDE	O
,	O
and	O
GPI	B
-	I
PLC	I
)	O
involved	O
in	O
the	O
transduction	O
of	O
the	O
insulin	B
signal	O
from	O
the	O
respective	O
receptor	O
systems	O
to	O
glycogen	O
synthase	O
and	O
phosphorylase	O

Leptin	B
and	O
UCP	B
(	O
1	O
and	O
2	O
)	O
mRNA	O
levels	O
were	O
determined	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
methodology	O
in	O
adipose	O
tissue	O
and	O
gastrocnemius	O
muscle	O

A	O
negative	O
correlation	O
between	O
WAT	O
O2	O
consumption	O
and	O
UCP2	B
expression	O
was	O
found	O
in	O
control	O
animals	O
,	O
but	O
not	O
in	O
the	O
cafeteria	O
-	O
fed	O
groups	O
,	O
suggesting	O
a	O
differential	O
response	O
to	O
the	O
beta3-adrenergic	O
compound	O
in	O
lean	O
and	O
obese	O
animals	O
,	O
which	O
is	O
in	O
agreement	O
with	O
the	O
reported	O
statistical	O
interactions	O
between	O
obesity	O
and	O
Trecadrine	O
administration	O
found	O
for	O
WAT	O
O2	O
consumption	O
and	O
muscle	O
UCP2	B
expression	O
,	O
as	O
well	O
as	O
for	O
plasma	O
leptin	B
and	O
WAT	O
leptin	B
expression	O

Arginine	B
vasopressin	I
(	O
AVP	O
)	O
and	O
lysophosphatidic	O
acid	O
(	O
LPA	O
)	O
have	O
been	O
shown	O
to	O
stimulate	O
protein	B
kinase	I
C	I
(	O
PKC	O
)	O
and	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinases	O
and	O
the	O
proliferation	O
of	O
vascular	O
smooth	O
muscle	O
cells	O

However	O
,	O
AVP	B
-	O
induced	O
activation	O
of	O
RSK2	O
,	O
a	O
downstream	O
substrate	O
of	O
ERK1	O
and	O
ERK2	O
,	O
was	O
PKC	B
-	O
dependent	O
and	O
PI	O
3-kinase	O
-	O
independent	O

PKC	B
was	O
necessary	O
in	O
AVP-	B
but	O
not	O
in	O
LPA	O
-	O
induced	O
activation	O
of	O
p70	O
S6	O
K	O

METHODS	O
:	O
We	O
have	O
therefore	O
studied	O
possible	O
associations	O
of	O
the	O
Gln27Glu	O
and	O
the	O
Gly16Arg	O
polymorphisms	O
in	O
the	O
beta2AR	O
with	O
BMI	O
,	O
plasma	O
leptin	B
and	O
UCP-1	B
mRNA	O
expression	O
in	O
the	O
intraperitoneal	O
adipose	O
tissue	O
in	O
a	O
population	O
of	O
Caucasian	O
women	O

Furthermore	O
,	O
no	O
association	O
was	O
found	O
between	O
the	O
Gln27Glu	O
or	O
the	O
Gly16Arg	O
polymorphisms	O
and	O
plasma	O
leptin	B
or	O
adipose	O
tissue	O
UCP-1	B
gene	O
expression	O
in	O
either	O
group	O

Oxytocin	B
central	O
injections	O
to	O
intact	O
animals	O
stimulated	O
insulin	B
synthesis	O
and	O
secretion	O
without	O
changing	O
of	O
islets	O
area	O

Thus	O
,	O
oxytocin	B
administration	O
stimulates	O
insulin	B
synthesis	O
and	O
secretion	O
in	O
intact	O
and	O
diabetic	O
animals	O
and	O
this	O
effect	O
is	O
more	O
expressed	O
with	O
central	O
injections	O

Hypothalamic	O
neuropeptide	B
Y	I
and	O
its	O
neuroendocrine	O
regulation	O
by	O
leptin	B

Aggregated	O
beta	O
amyloid	B
peptide	O
1	O
-	O
40	O
decreases	O
Ca2	O
+	O
-	O
and	O
cholinergic	O
receptor	O
-	O
mediated	O
phosphoinositide	O
degradation	O
by	O
alteration	O
of	O
membrane	O
and	O
cytosolic	O
phospholipase	B
C	I
in	O
brain	O
cortex	O

The	O
effects	O
of	O
full	O
-	O
length	O
amyloid	B
beta	O
protein	O
,	O
A	O
(	O
beta	O
)	O
(	O
1	O
-	O
40	O
)	O
,	O
on	O
phosphoinositide	O
-	O
specific	O
phospholipase	B
C	I
(	O
PLC	O
)	O
were	O
investigated	O
in	O
synaptic	O
plasma	O
membranes	O
(	O
SPM	O
)	O
and	O
cytosol	O
prepared	O
from	O
the	O
cerebral	O
cortex	O
of	O
adult	O
rats	O

Aggregated	O
A	B
(	I
beta	I
)	I
also	O
decreased	O
significantly	O
the	O
level	O
of	O
diacylglycerol	O
,	O
the	O
product	O
of	O
PLC	B

This	O
additionally	O
supports	O
the	O
inhibitory	O
effect	O
of	O
A	B
(	I
beta	I
)	I
on	O
membrane	O
-	O
bound	O
and	O
cytosolic	O
PLC	B

Moreover	O
,	O
A	B
(	I
beta	I
)	I
(	I
1	I
-	I
40	I
)	I
significantly	O
decreased	O
the	O
basal	O
activity	O
of	O
the	O
PIP2-PLC	B
in	O
SPM	O
and	O
the	O
enzyme	O
activity	O
regulated	O
through	O
cholinergic	O
receptors	O

Ten	O
protein	B
kinases	I
have	O
been	O
assayed	O
for	O
their	O
ability	O
to	O
phosphorylate	O
in	O
vitro	O
the	O
recombinant	B
bovine	I
PrP	I
(	O
25	O
-	O
242	O
)	O
(	O
rbPrP	O
)	O

With	O
regard	O
to	O
CK2	B
,	O
phosphorylation	O
occurs	O
at	O
Ser	O
154	O
with	O
a	O
stoichiometry	O
of	O
about	O
0.1	O
mol	O
phosphate	O
/	O
mol	O
rbPrP	B
,	O
which	O
is	O
doubled	O
by	O
mild	O
heat	O
treatment	O
of	O
rbPrP	B

Furthermore	O
,	O
in	O
SN-56	O
/	O
OBR	O
cells	O
both	O
CNTF	O
and	O
leptin	B
produce	O
changes	O
in	O
neurotransmitter	O
and	O
neuropeptide	O
phenotype	O
characteristic	O
of	O
cholinergic	O
neurons	O
,	O
such	O
as	O
an	O
increase	O
in	O
choline	O
acetyltransferase	O
and	O
vasoactive	O
intestinal	O
polypeptide	O
,	O
and	O
a	O
decrease	O
in	O
neuropeptide	B
Y	I
expression	O

We	O
examined	O
for	O
the	O
first	O
time	O
in	O
young	O
men	O
effects	O
of	O
intravenous	O
injections	O
of	O
NPY	B
(	O
4x50	O
or	O
100	O
microg	O
,	O
n	O
=	O
9	O
and	O
11	O
,	O
respectively	O
,	O
at	O
22.00	O
,	O
23.00	O
,	O
24.00	O
and	O
01.00	O
compared	O
to	O
saline	O
)	O
on	O
the	O
sleep	O
electroencephalogram	O
(	O
EEG	O
;	O
recorded	O
from	O
23.00	O
to	O
07.00	O
)	O
and	O
nocturnal	O
secretion	O
of	O
adrenocorticotrophic	O
hormone	O
(	O
ACTH	O
)	O
,	O
cortisol	O
,	O
growth	O
hormone	O
(	O
GH	O
)	O
,	O
prolactin	O
and	O
leptin	B

Interestingly	O
,	O
both	O
5-HT	O
and	O
leptin	B
modulate	O
the	O
action	O
of	O
NPY	B
,	O
which	O
may	O
form	O
a	O
part	O
of	O
a	O
common	O
output	O
pathway	O
for	O
the	O
expression	O
of	O
appetite	O

The	O
glycosyl	O
-	O
phosphatidylinositol	O
anchored	O
protein	O
,	O
membrane	O
dipeptidase	O
(	O
EC	O
3.4.13.19	O
)	O
is	O
released	O
from	O
the	O
surface	O
of	O
3T3-L1	O
adipocytes	O
in	O
response	O
to	O
insulin	B
treatment	O
through	O
the	O
action	O
of	O
a	O
phospholipase	B
C	I

Although	O
X	O
-	O
Pro	O
aminopeptidase	O
(	O
EC	O
3.4.11.9	O
)	O
is	O
GPI	O
-	O
anchored	O
in	O
3T3-L1	O
adipocytes	O
as	O
shown	O
by	O
digestion	O
with	O
bacterial	O
phosphatidylinositol	O
-	O
specific	O
phospholipase	B
C	I
,	O
it	O
was	O
not	O
released	O
upon	O
insulin	B
treatment	O
of	O
the	O
cells	O
,	O
indicating	O
that	O
only	O
a	O
subset	O
of	O
the	O
GPI	O
-	O
anchored	O
proteins	O
are	O
susceptible	O
to	O
insulin	B
-	O
stimulated	O
release	O

However	O
,	O
neither	O
progesterone	O
nor	O
insulin	B
increased	O
phosphotyrosine	O
on	O
PLCgamma	B

They	O
are	O
needed	O
for	O
the	O
catabolism	O
of	O
cholesterol	B
,	O
bile	O
acids	O
,	O
and	O
steroid	O
hormones	O
;	O
they	O
hydrolyze	O
a	O
number	O
of	O
flavonoid	B
glycosides	O
to	O
anticarcinogens	O
;	O
and	O
they	O
detoxify	O
certain	O
carcinogens	O

Thus	O
,	O
highly	O
expressed	O
in	O
human	O
adipocytes	O
,	O
the	O
Y	O
(	O
1	O
)	O
receptor	O
sustains	O
the	O
strong	O
antilipolytic	O
effect	O
of	O
NPY	B
and	O
exerts	O
a	O
positive	O
action	O
on	O
leptin	B
secretion	O

Induction	O
of	O
fatty	O
acid	O
translocase	O
/	O
CD36	O
,	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
-	O
gamma2	O
,	O
leptin	B
,	O
uncoupling	B
proteins	I
2	I
and	O
3	B
,	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
gene	O
expression	O
in	O
human	O
subcutaneous	O
fat	O
by	O
lipid	O
infusion	O

Using	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
analysis	O
,	O
the	O
mRNA	O
expression	O
of	O
fatty	O
acid	O
translocase	O
(	O
FAT	O
)	O
/	O
CD36	O
,	O
PPAR	O
-	O
gamma2	O
,	O
leptin	B
,	O
uncoupling	B
protein	I
(	I
UCP	I
)	I
-2	I
and	O
UCP-3	B
,	O
and	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-alpha	O
was	O
investigated	O
in	O
gluteal	O
subcutaneous	O
fat	O
biopsies	O
before	O
and	O
after	O
5	O
h	O
infusions	O
of	O
saline	O
or	O
Intralipid	O
(	O
Pharmacia	O
and	O
Upjohn	O
,	O
Milan	O
,	O
Italy	O
)	O
plus	O
heparin	O
,	O
which	O
does	O
not	O
modify	O
insulinemia	O

Marked	O
increases	O
in	O
FAT	O
/	O
CD36	O
(	O
724+	O
/	O
-18	O
%	O
;	O
P	O
<	O
0.05	O
)	O
,	O
PPAR	O
-	O
gamma2	O
(	O
200+	O
/	O
-8	O
%	O
;	O
P	O
<	O
0.05	O
)	O
,	O
leptin	B
(	O
110+	O
/	O
-13	O
%	O
;	O
P	O
<	O
0.05	O
)	O
,	O
UCP-2	B
(	O
120+	O
/	O
-7	O
%	O
;	O
P	O
<	O
0.05	O
)	O
,	O
UCP-3	B
(	O
80+	O
/	O
-5	O
%	O
;	O
P	O
<	O
0.05	O
)	O
,	O
and	O
TNF	O
-	O
alpha	O
mRNA	O
(	O
130+	O
/	O
-12	O
%	O
;	O
P	O
<	O
0.05	O
)	O
were	O
observed	O
in	O
comparison	O
with	O
pretreatment	O
levels	O
,	O
whereas	O
there	O
was	O
no	O
change	O
after	O
saline	O
infusion	O

These	O
data	O
suggest	O
that	O
the	O
in	O
vivo	O
gene	O
expression	O
of	O
FAT	O
/	O
CD36	O
,	O
PPAR	O
-	O
gamma2	O
,	O
leptin	B
,	O
UCP-2	B
,	O
UCP-3	B
,	O
and	O
TNF	O
-	O
alpha	O
in	O
subcutaneous	O
adipose	O
tissue	O
is	O
regulated	O
by	O
circulating	O
lipids	O
independent	O
of	O
insulin	O
and	O
that	O
prolonged	O
hyperlipidemia	O
may	O
therefore	O
contribute	O
to	O
increased	O
fat	O
metabolism	O
and	O
storage	O
as	O
a	O
result	O
of	O
the	O
increased	O
expression	O
of	O
these	O
proteins	O

The	O
protein	B
kinase	I
C	I
specific	O
inhibitor	O
Go-6983	O
further	O
enhanced	O
the	O
inhibitory	O
effect	O
of	O
VACM-1	O
on	O
AVP	B
-	O
stimulated	O
cAMP	O
production	O

Pretreatment	O
of	O
HEK-293	O
cells	O
for	O
2	O
min	O
with	O
carbachol	O
,	O
a	O
mAChR	O
agonist	O
,	O
lysophosphatidic	O
acid	O
,	O
or	O
ATP	O
,	O
followed	O
by	O
agonist	O
washout	O
,	O
strongly	O
increased	O
(	O
by	O
2	O
-	O
3-fold	O
)	O
maximal	O
PLC	B
stimulation	O
(	O
measured	O
>	O
/=40	O
min	O
later	O
)	O
by	O
epidermal	O
growth	O
factor	O
and	O
platelet	O
-	O
derived	O
growth	O
factor	O
,	O
but	O
not	O
insulin	B
,	O
and	O
largely	O
enhanced	O
PLC	B
sensitivity	O
to	O
these	O
RTK	O
agonists	O

Involvement	O
of	O
thyroid	O
hormones	O
in	O
the	O
effect	O
of	O
intracerebroventricular	O
leptin	B
infusion	O
on	O
uncoupling	B
protein-3	I
expression	O
in	O
rat	O
muscle	O

A	O
reduction	O
of	O
food	O
intake	O
imposed	O
on	O
control	O
rats	O
(	O
pair	O
-	O
feeding	O
)	O
,	O
aimed	O
at	O
mimicking	O
leptin	B
-	O
induced	O
hyperphagia	O
,	O
produced	O
a	O
marked	O
decrease	O
in	O
the	O
expression	O
of	O
muscle	O
uncoupling	B
protein-3	I
(	O
UCP-3	O
)	O
,	O
whereas	O
ICV	O
infusion	O
of	O
leptin	B
prevented	O
such	O
a	O
decrease	O
in	O
UCP-3	B

To	O
further	O
substantiate	O
an	O
involvement	O
of	O
thyroid	O
hormones	O
in	O
the	O
effect	O
of	O
leptin	B
on	O
muscle	O
UCP-3	B
expression	O
,	O
hypothyroid	O
rats	O
were	O
ICV	O
infused	O
with	O
leptin	B
or	O
vehicle	O

It	O
was	O
observed	O
that	O
in	O
hypothyroid	O
rats	O
,	O
ICV	O
leptin	B
was	O
unable	O
to	O
maintain	O
muscle	O
UCP-3	B
expression	O
at	O
values	O
measured	O
in	O
ad	O
libitum	O
fed	O
controls	O

These	O
results	O
suggest	O
that	O
central	O
leptin	B
stimulates	O
T3	O
production	O
via	O
an	O
activation	O
of	O
T4	O
to	O
T3	O
conversion	O
,	O
and	O
that	O
this	O
stimulation	O
could	O
be	O
responsible	O
for	O
the	O
effect	O
of	O
leptin	B
on	O
muscle	O
UCP-3	B
expression	O

The	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
leptin	B
,	O
plasma	O
neuropeptide	B
Y	I
(	O
NPY	O
)	O
,	O
serotonin	O
,	O
thyroxine	O
(	O
T4	O
)	O
,	O
triiodothyronine	O
(	O
T3	O
)	O
and	O
reverse	O
triiodothyronine	O
(	O
rT3	O
)	O
in	O
serum	O
were	O
evaluated	O
for	O
each	O
subject	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
hCG	O
,	O
hCG	O
plus	O
oxytocin	B
and	O
oxytocin	B
on	O
[	O
3H	O
]	O
inositol	B
phosphate	I
(	O
IP	O
)	O
formations	O
in	O
porcine	O
myometrial	O
cells	O
obtained	O
from	O
ovariectomized	O
and	O
cyclic	O
gilts	O

The	O
highest	O
production	O
of	O
total	O
inositol	B
phosphates	I
(	O
d.p.m	O
.	O
)	O
was	O
found	O
in	O
cells	O
from	O
ovariectomized	O
gilts	O
given	O
in	O
vivo	O
estradiol	O
benzoate	O
and	O
progesterone	O
for	O
five	O
consecutive	O
days	O
and	O
treated	O
with	O
1000	O
mU	O
hCG	O
and	O
100	O
mU	O
hCG	O
plus	O
1	O
microM	O
oxytocin	B
(	O
984	O
+	O
/-	O
84	O
and	O
1063	O
+	O
/-	O
131	O
vs	O
314	O
+	O
/-	O
36	O
,	O
respectively	O
)	O

There	O
was	O
also	O
a	O
very	O
significant	O
increase	O
of	O
IP1	B
after	O
the	O
addition	O
of	O
1000	O
mU	O
hCG	O
(	O
p	O
<	O
0.001	O
)	O
and	O
IP1	B
and	O
IP3	B
when	O
1000	O
mU	O
hCG	O
plus	O
oxytocin	B
were	O
added	O
(	O
p	O
<	O
0.001	O
and	O
p	O
<	O
0.01	O
,	O
respectively	O
)	O

Only	O
oxytocin	B
alone	O
increased	O
the	O
formation	O
of	O
IPs	B
in	O
cells	O
from	O
ovariectomized	O
pigs	O
treated	O
with	O
estradiol	O
in	O
vivo	O
(	O
p	O
<	O
0.01	O
)	O

The	O
highest	O
dose	O
of	O
hCG	O
plus	O
The	O
highest	O
dose	O
of	O
hCG	O
plus	O
oxytocin	B
provoked	O
accumulation	O
of	O
total	O
[	O
3H	O
]	O
inositol	B
phosphate	I
(	O
p	O
<	O
0.05	O
)	O
53	O
%	O
over	O
the	O
basal	O
level	O
on	O
days	O
21	O
/	O
1	O
of	O
the	O
estrous	O
cycle	O

The	O
present	O
study	O
demonstrates	O
that	O
hCG	O
and	O
oxytocin	B
can	O
increase	O
the	O
accumulation	O
of	O
inositol	B
phosphates	I
in	O
porcine	O
myometrial	O
cells	O

Influence	O
of	O
obesity	O
and	O
menopausal	O
status	O
on	O
serum	O
leptin	B
,	O
cholecystokinin	O
,	O
galanin	O
and	O
neuropeptide	B
Y	I
levels	O

Obesity	O
occurs	O
in	O
60	O
%	O
of	O
women	O
after	O
menopause	O
and	O
is	O
characterized	O
by	O
an	O
excess	O
of	O
adipose	O
tissue	O
that	O
depends	O
on	O
several	O
orexigenic	O
(	O
neuropeptide	B
Y	I
(	O
NPY	O
)	O
stimulates	O
carbohydrate	O
ingestion	O
,	O
galanin	O
stimulates	O
fat	O
intake	O
)	O
and	O
anorectic	O
(	O
leptin	B
,	O
cholecystokinin	O
(	O
CCK	O
)	O
)	O
factors	O

Both	O
leptin	B
and	O
insulin	O
can	O
reduce	O
hypothalamic	O
NPY	B
production	O
and	O
secretion	O

We	O
investigated	O
basal	O
levels	O
of	O
serum	O
leptin	B
,	O
CCK	O
,	O
galanin	O
and	O
NPY	B
in	O
16	O
non	O
-	O
obese	O
premenopausal	O
women	O
,	O
in	O
15	O
obese	O
premenopausal	O
women	O
(	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
34.6	O
+	O
/-	O
1.3	O
SD	O
)	O
and	O
in	O
ten	O
obese	O
postmenopausal	O
women	O
(	O
BMI	O
34.7	O
+	O
/-	O
1.5	O
SD	O
)	O
to	O
determine	O
the	O
relationship	O
between	O
obesity	O
,	O
menopause	O
and	O
these	O
neuropeptides	O

Significantly	O
increased	O
leptin	B
and	O
galanin	O
levels	O
in	O
postmenopausal	O
obese	O
women	O
coupled	O
with	O
decreased	O
NPY	B
levels	O
revealed	O
some	O
changes	O
in	O
the	O
neuropeptides	O
regulating	O
eating	O
behavior	O
,	O
which	O
may	O
be	O
the	O
reason	O
for	O
the	O
onset	O
of	O
postmenopausal	O
obesity	O

Phospholipase	B
C	I
(	O
PLC	O
)	O
activity	O
was	O
investigated	O
by	O
stimulation	O
of	O
membrane	O
preparations	O
obtained	O
from	O
insulin	B
(	O
beta	O
-	O
TC3	O
)	O
-	O
,	O
somatostatin	O
(	O
Rin	O
1027-B2	O
)	O
-	O
,	O
and	O
glucagon	O
(	O
INR1-G9	O
)	O
-producing	O
pancreatic	O
cell	O
lines	O
using	O
the	O
non	O
-	O
hydrolyzable	O
GTP	O
analogue	O
GTPgammaS	O
alone	O
,	O
the	O
C	O
-	O
terminal	O
octapeptide	O
cholecystokinin	O
(	O
CCK-8	O
)	O
,	O
or	O
gastrin	O

Therefore	O
,	O
it	O
was	O
examined	O
whether	O
stimulation	O
of	O
Swiss	O
3T3	O
cells	O
with	O
insulin	B
causes	O
changes	O
in	O
the	O
subcellular	O
distribution	O
of	O
EGF	O
receptors	O
and	O
phospholipase	B
Cgamma1	I
that	O
could	O
potentially	O
explain	O
the	O
observed	O
synergy	O
or	O
costimulation	O
.	O

However	O
,	O
both	O
EGF	O
and	O
insulin	B
stimulated	O
the	O
accumulation	O
of	O
phospholipase	B
Cgamma1	I
at	O
the	O
actin	O
arc	O
,	O
which	O
was	O
coincident	O
with	O
the	O
EGF	O
receptor	O
in	O
the	O
case	O
of	O
insulin-	B
stimulated	O
cells	O
.	O

Therefore	O
,	O
it	O
is	O
suggested	O
that	O
the	O
insulin	B
-	O
induced	O
coclustering	O
of	O
the	O
EGF	O
receptor	O
with	O
phospholipase	B
Cgamma1	I
at	O
the	O
actin	O
arc	O
may	O
allow	O
for	O
greater	O
efficiency	O
of	O
signal	O
transduction	O
,	O
resulting	O
in	O
the	O
synergy	O
observed	O
for	O
these	O
two	O
hormones	O
in	O
stimulation	O
of	O
DNA	O
synthesis	O
.	O

Although	O
the	O
above	O
data	O
are	O
consistent	O
with	O
a	O
direct	O
ability	O
of	O
leptin	B
to	O
promote	O
TRH	O
biosynthesis	O
through	O
actions	O
on	O
TRH	O
neurons	O
,	O
addition	O
of	O
a	O
-	O
MSH	O
produced	O
a	O
3.5	O
fold	O
increase	O
in	O
TRH	O
biosynthesis	O
and	O
release	O
,	O
whereas	O
NPY	B
treatment	O
suppressed	O
~3	O
fold	O
proTRH	O
biosynthesis	O

For	O
example	O
,	O
leptin	B
suppresses	O
neuropeptide	B
Y	I
(	O
NPY	O
)	O
expression	O
in	O
the	O
arcuate	O
nucleus	O

As	O
expected	O
,	O
in	O
fusion	O
of	O
NPY	B
alone	O
(	O
18	O
microg	O
/	O
day	O
)	O
augmented	O
food	O
intake	O
(	O
191.6	O
%	O
over	O
the	O
initial	O
control	O
,	O
P	O
<	O
0.05	O
)	O
and	O
produced	O
a	O
25.1	O
%	O
weight	O
gain	O
in	O
conjunction	O
with	O
a	O
10-fold	O
increase	O
in	O
serum	O
leptin	B
concentrations	O
at	O
the	O
end	O
of	O
the	O
7-day	O
period	O

Interestingly	O
,	O
coinfusion	O
of	O
this	O
regimen	O
of	O
NPY	B
with	O
the	O
highly	O
effective	O
anorectic	O
and	O
body	O
reducing	O
effects	O
of	O
CNTF	O
(	O
5.0	O
microg	O
/	O
day	O
)	O
not	O
only	O
prevented	O
the	O
CNTF	O
-	O
induced	O
anorexia	O
and	O
weight	O
loss	O
,	O
but	O
also	O
normalized	O
serum	O
leptin	B
concentrations	O
and	O
hypothalamic	O
NPY	B
gene	O
expression	O

These	O
results	O
demonstrate	O
that	O
chronic	O
central	O
infusion	O
to	O
produce	O
a	O
persistent	O
elevation	O
of	O
the	O
cytokine	O
at	O
pathophysiological	O
levels	O
(	O
a	O
situation	O
that	O
may	O
normally	O
manifest	O
during	O
infection	O
,	O
injury	O
and	O
inflammation	O
)	O
produced	O
severe	O
anorexia	O
and	O
weight	O
loss	O
in	O
conjunction	O
with	O
reduction	O
in	O
both	O
serum	O
leptin	B
concentrations	O
and	O
hypothalamic	O
NPY	B
gene	O
expression	O

A	O
caveolin-1-dependent	O
coupling	O
of	O
PrPc	B
to	O
the	O
tyrosine	B
kinase	I
Fyn	I
was	O
observed	O

Recently	O
several	O
significant	O
advances	O
have	O
been	O
made	O
in	O
this	O
area	O
,	O
including	O
the	O
identification	O
of	O
the	O
appetite	O
regulating	O
hormone	O
,	O
leptin	B
,	O
and	O
a	O
detailed	O
understanding	O
of	O
its	O
targets	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
such	O
as	O
neuropeptide	B
Y	I
(	O
NPY	O
)	O
and	O
the	O
melanocortin-4	O
receptor	O

The	O
relative	O
risks	O
between	O
highest	O
and	O
lowest	O
quarters	O
of	O
flavonoid	B
intake	O
adjusted	O
for	O
age	O
,	O
smoking	O
,	O
serum	O
cholesterol	B
concentration	O
,	O
blood	O
pressure	O
,	O
and	O
body	O
mass	O
index	O
were	O
0.69	O
(	O
95	O
%	O
confidence	O
interval	O
0.53	O
to	O
0.90	O
)	O
and	O
0.54	O
(	O
0.33	O
to	O
0.87	O
)	O
for	O
total	O
and	O
coronary	O
mortality	O
,	O
respectively	O

The	O
effect	O
of	O
leptin	B
in	O
adult	O
rats	O
appears	O
to	O
be	O
exerted	O
at	O
hypothalamic	O
level	O
by	O
regulating	O
growth	O
hormone	O
releasing	O
hormone	O
(	O
GHRH	O
)	O
,	O
somatostatin	O
and	O
neuropeptide	B
Y	I
(	O
NPY	O
)	O
-producing	O
neurones	O

Plasma	O
insulin	O
,	O
cholecystokinin	O
,	O
galanin	O
,	O
neuropeptide	B
Y	I
and	O
leptin	B
levels	O
in	O
obese	O
women	O
with	O
and	O
without	O
type	O
2	O
diabetes	O
mellitus	O

Experimental	O
studies	O
provided	O
evidences	O
that	O
leptin	B
,	O
cholecystokinin	O
(	O
CCK	O
)	O
,	O
galanin	O
(	O
GAL	O
)	O
,	O
neuropeptide	B
Y	I
(	O
NPY	O
)	O
and	O
insulin	O
are	O
involved	O
in	O
feeding	O
behaviour	O

Plasma	O
concentrations	O
of	O
FSH	O
,	O
leptin	B
,	O
CCK	O
,	O
GAL	O
,	O
NPY	B
and	O
insulin	O
were	O
determined	O
using	O
commercial	O
RIA	O
kits	O

Our	O
results	O
,	O
ie	O
higher	O
mean	O
plasma	O
NPY	B
levels	O
in	O
postmenopausal	O
diabetic	O
women	O
and	O
positive	O
correlation	O
of	O
CCK	O
with	O
leptin	B
and	O
insulin	O
,	O
may	O
suggest	O
the	O
role	O
of	O
these	O
neuropeptides	O
in	O
metabolic	O
disorders	O
leading	O
to	O
type	O
2	O
diabetes	O
mellitus	O

These	O
results	O
suggest	O
that	O
T3	O
may	O
increase	O
UCP	B
family	O
expression	O
independent	O
of	O
leptin	B
action	O

The	O
ARC	O
NPY	B
neurones	O
are	O
stimulated	O
by	O
starvation	O
,	O
probably	O
mediated	O
by	O
falls	O
in	O
circulating	O
leptin	B
and	O
insulin	O
(	O
which	O
both	O
inhibit	O
these	O
neurones	O
)	O
,	O
and	O
contribute	O
to	O
the	O
increased	O
hunger	O
in	O
this	O
and	O
other	O
conditions	O
of	O
energy	O
deficit	O

ARC	O
NPY	B
neurones	O
also	O
mediate	O
hyperphagia	O
and	O
obesity	O
in	O
the	O
ob	O
/	O
ob	O
and	O
db	O
/	O
db	O
mice	O
and	O
fa	O
/	O
fa	O
rat	O
,	O
in	O
which	O
leptin	B
inhibition	O
is	O
lost	O
through	O
mutations	O
affecting	O
leptin	B
or	O
its	O
receptor	O

Granulosa	O
cells	O
were	O
isolated	O
from	O
bovine	O
preovulatory	O
follicles	O
and	O
cultured	O
for	O
3	O
days	O
with	O
or	O
without	O
OT	B
in	O
medium	O
supplemented	O
with	O
either	O
insulin	B
(	O
1	O
microgram	O
/	O
ml	O
)	O
+	O
1	O
%	O
fetal	O
calf	O
serum	O
(	O
FCS	O
)	O
,	O
which	O
maintains	O
basal	O
estradiol	O
secretion	O
,	O
or	O
low	O
doses	O
of	O
FSH	O
(	O
1	O
and	O
2	O
ng	O
/	O
ml	O
)	O
+	O
1	O
%	O
FCS	O
,	O
a	O
culture	O
condition	O
that	O
maximizes	O
effects	O
of	O
FSH	O
on	O
estradiol	O
secretion	O

Similarly	O
,	O
central	O
leptin	B
treatment	O
also	O
had	O
a	O
greater	O
effect	O
in	O
suppressing	O
hypothalamic	O
NPY	B
mRNA	O
expression	O
in	O
young	O
(	O
-23+	O
/	O
-4	O
%	O
)	O
than	O
in	O
old	O
(	O
-8+	O
/	O
-4	O
%	O
)	O
rats	O
compared	O
with	O
their	O
age	O
-	O
matched	O
pair	O
-	O
fed	O
treated	O
rats	O

Compared	O
with	O
the	O
wild	O
type	O
,	O
GA	B
induction	O
of	O
alpha	B
-	I
amylase	I
activity	O
in	O
aleurone	O
cells	O
of	O
d1	O
was	O
greatly	O
reduced	O

Relative	O
to	O
the	O
wild	O
type	O
,	O
the	O
GA	B
(	O
3	O
)	O
-treated	O
aleurone	O
layer	O
of	O
d1	O
had	O
lower	O
expression	O
of	O
Ramy1A	O
,	O
which	O
encodes	O
alpha	B
-	I
amylase	I
,	O
and	O
OsGAMYB	O
,	O
which	O
encodes	O
a	O
GA	B
-	O
inducible	O
transcriptional	O
factor	O
,	O
and	O
no	O
increase	O
in	O
expression	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-ATPase	O

However	O
,	O
in	O
the	O
presence	O
of	O
high	O
GA	B
concentrations	O
,	O
alpha	B
-	I
amylase	I
induction	O
occurred	O
even	O
in	O
d1	O

All	O
these	O
results	O
suggest	O
that	O
d1	O
affects	O
a	O
part	O
of	O
the	O
GA	B
-	O
signaling	O
pathway	O
,	O
namely	O
the	O
induction	O
of	O
alpha	B
-	I
amylase	I
in	O
the	O
aleurone	O
layer	O
and	O
internode	O
elongation	O

Finally	O
,	O
recent	O
evidences	O
suggest	O
that	O
melanocortins	O
could	O
be	O
involved	O
in	O
mediating	O
the	O
effects	O
of	O
leptin	B
,	O
and	O
in	O
controlling	O
the	O
expression	O
of	O
neuropeptide	B
Y	I
(	O
NPY	O
)	O

Insulin	B
-	O
induced	O
phospholipase	O
D1	O
and	O
phospholipase	O
D2	O
activity	O
in	O
human	O
embryonic	O
kidney-293	O
cells	O
mediated	O
by	O
the	O
phospholipase	B
Cgamma	I
and	O
protein	O
kinase	O
Calpha	O
signalling	O
cascade	O
.	O

Co	O
-	O
expression	O
of	O
PLD1	O
with	O
phospholipase	B
C	I
(	I
PLC	I
)	I
gamma	I
has	O
the	O
same	O
effect	O
,	O
while	O
co	O
-	O
expression	O
of	O
PLD2	O
with	O
PLCgamma	B
allows	O
PLD2	O
activity	O
to	O
be	O
stimulated	O
in	O
an	O
insulin	B
-	O
dependent	O
manner	O
.	O

The	O
PKC	O
-	O
specific	O
inhibitors	O
bisindolylmaleimide	O
and	O
Go	O
6976	O
abolish	O
insulin	B
-	O
induced	O
PLD2	O
activation	O
in	O
HEK-293	O
cells	O
co	O
-	O
expressing	O
the	O
insulin	O
receptor	O
,	O
PLCgamma	B
and	O
PLD2	O
,	O
confirming	O
that	O
not	O
only	O
PLD1	O
,	O
but	O
PLD2	O
as	O
well	O
,	O
is	O
regulated	O
in	O
a	O
PKC	O
-	O
dependent	O
manner	O
.	O

In	O
summary	O
,	O
we	O
demonstrate	O
that	O
insulin	B
treatment	O
results	O
in	O
activation	O
of	O
both	O
PLD1	O
and	O
PLD2	O
in	O
appropriate	O
cell	O
types	O
when	O
the	O
appropriate	O
upstream	O
intermediate	O
signalling	O
components	O
,	O
i.e.	O
PKCalpha	O
and	O
PLCgamma	B
,	O
are	O
expressed	O
at	O
sufficient	O
levels	O
.	O

Leptin	B
Rapidly	O
Inhibits	O
Hypothalamic	O
Neuropeptide	B
Y	I
Secretion	O
and	O
Stimulates	O
Corticotropin	O
-	O
Releasing	O
Hormone	O
Secretion	O
in	O
Adrenalectomized	O
Mice	O

Leptin	B
may	O
rapidly	O
inhibit	O
food	O
intake	O
by	O
altering	O
the	O
secretion	O
of	O
hypothalamic	O
neuropeptides	O
such	O
as	O
neuropeptide	B
Y	I
(	O
NPY	O
)	O
,	O
a	O
stimulator	O
of	O
food	O
intake	O
,	O
and/or	O
corticotropin	O
-	O
releasing	O
hormone	O
(	O
CRH	O
)	O
,	O
an	O
inhibitor	O
of	O
food	O
intake	O

We	O
measured	O
concentrations	O
of	O
NPY	B
and	O
CRH	O
in	O
specific	O
hypothalamic	O
regions	O
[	O
i.e.	O
,	O
arcuate	O
nucleus	O
(	O
ARC	O
)	O
,	O
paraventricular	O
nucleus	O
(	O
PVN	O
)	O
,	O
ventromedial	O
nucleus	O
and	O
dorsomedial	O
nucleus	O
]	O
of	O
7-	O
to	O
8-wk	O
-	O
old	O
lean	O
and	O
ob	O
/	O
ob	O
mice	O
at	O
1	O
or	O
3	O
h	O
after	O
intracerebroventricular	O
leptin	B
administration	O

No	O
rapid	O
-	O
onset	O
effects	O
of	O
leptin	B
on	O
hypothalamic	O
NPY	B
or	O
CRH	O
concentrations	O
were	O
observed	O
in	O
intact	O
mice	O

The	O
addition	O
of	O
leptin	B
to	O
hypothalamic	O
preparations	O
from	O
intact	O
mice	O
also	O
did	O
not	O
alter	O
NPY	B
or	O
CRH	O
secretion	O

Within	O
20	O
min	O
after	O
exposure	O
to	O
leptin	B
,	O
NPY	B
secretion	O
from	O
hypothalamic	O
preparations	O
obtained	O
from	O
adrenalectomized	O
mice	O
was	O
lowered	O
by	O
27	O
%	O
and	O
CRH	O
secretion	O
was	O
elevated	O
by	O
51	O
%	O

The	O
current	O
study	O
demonstrates	O
that	O
leptin	B
rapidly	O
influences	O
the	O
secretion	O
of	O
hypothalamic	O
NPY	B
and	O
CRH	O
and	O
that	O
these	O
actions	O
of	O
leptin	B
within	O
the	O
hypothalamus	O
are	O
restrained	O
by	O
the	O
presence	O
of	O
endogenous	O
corticosterone	O

Arcuate	O
nucleus	O
NPY	B
mRNA	O
increased	O
in	O
rats	O
given	O
protein	O
-	O
free	O
diet	O
,	O
correlating	O
with	O
leptin	B
rather	O
than	O
decreased	O
feeding	O

SP	O
ewes	O
also	O
had	O
greater	O
incorporation	O
of	O
[	O
3H	O
]	O
inositol	O
into	O
inositol	B
trisphosphate	I
(	O
IP3	O
)	O
(	O
+	O
3449	O
%	O
,	O
p	O
less	O
than	O
0.01	O
)	O
and	O
total	O
inositol	B
phosphate	I
(	O
IP	O
)	O
(	O
+	O
760	O
%	O
,	O
p	O
less	O
than	O
0.08	O
)	O
,	O
in	O
response	O
to	O
oxytocin	B
,	O
than	O
did	O
oCSP	O
ewes	O
(	O
+	O
553	O
and	O
+	O
168	O
%	O
for	O
IP3	B
and	O
total	O
IP	B
,	O
respectively	O
)	O
in	O
endometrium	O
collected	O
at	O
ovariectomy	O
/	O
hysterectomy	O
on	O
Day	O
16	O

These	O
results	O
indicate	O
that	O
oTP-1	O
may	O
prevent	O
luteolysis	O
by	O
inhibiting	O
development	O
of	O
endometrial	O
responsiveness	O
to	O
oxytocin	B
and	O
,	O
therefore	O
,	O
reduce	O
oxytocin	B
-	O
induced	O
synthesis	O
of	O
IP3	B
and	O
PGF2	O
alpha	O

Once	O
the	O
abnormally	O
phosphorylated	O
abnormal	O
prion	B
protein	I
isoform	O
agent	O
is	O
initiated	O
,	O
any	O
stress	O
event	O
ensuing	O
in	O
adult	O
life	O
induces	O
a	O
nerve	O
growth	O
factor	O
-	O
mediated	O
synthesis	O
of	O
normal	O
cellular	O
prion	B
protein	I
isoform	O
that	O
aggregates	O
to	O
abnormally	O
phosphorylated	O
abnormal	O
prion	B
protein	I
isoform	O
,	O
thereby	O
becoming	O
'	O
infected'	O
/	O
transformed	O
into	O
the	O
same	O
;	O
due	O
to	O
the	O
vicious	O
circle	O
of	O
positive	O
feedback	O
invoked	O
by	O
the	O
blocking	O
of	O
a	O
prion	B
protein	I
-	O
specific	O
kinase	B

The	O
resulting	O
abnormally	O
phosphorylated	O
PrPsc	B
aggregates	O
to	O
freshly	O
synthesized	O
PrPc	B
,	O
transforming	O
it	O
into	O
same	O
;	O
due	O
to	O
a	O
system	O
of	O
positive	O
feedback	O
invoked	O
by	O
the	O
organophosphate	O
-	O
induced	O
blockage	O
of	O
a	O
prion	B
protein	I
-	O
specific	O
protein	B
kinase	I
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
how	O
oxytocin	B
given	O
subcutaneously	O
(	O
SC	O
)	O
and	O
intracerebroventricularly	O
(	O
ICV	O
)	O
influences	O
the	O
secretion	O
of	O
insulin	B
,	O
glucagon	O
and	O
glucose	O
and	O
to	O
investigate	O
whether	O
the	O
effect	O
on	O
these	O
variables	O
of	O
suckling	O
in	O
lactating	O
rats	O
is	O
mediated	O
by	O
oxytocinergic	O
mechanisms	O

Subcutaneous	O
injections	O
of	O
oxytocin	B
increased	O
insulin	B
,	O
glucagon	O
and	O
glucose	O
levels	O
significantly	O

Two	O
nanograms	O
oxytocin	B
given	O
ICV	O
had	O
no	O
effect	O
on	O
glucagon	O
and	O
glucose	O
levels	O
but	O
caused	O
a	O
significant	O
rise	O
in	O
insulin	B
levels	O
at	O
this	O
time	O
point	O

The	O
oxytocin	B
antagonist	O
1-deamino-2-D	O
-	O
Tyr-	O
(	O
OEt	O
)	O
-4-Thr-8-Orn	O
-	O
oxytocin	O
administered	O
ICV	O
increased	O
insulin	B
levels	O
itself	O
and	O
therefore	O
the	O
effect	O
on	O
oxytocin	B
-	O
induced	O
insulin	B
secretion	O
was	O
difficult	O
to	O
evaluate	O

Intracerebroventricular	O
injections	O
of	O
200	O
ng	O
oxytocin	B
caused	O
a	O
significant	O
rise	O
not	O
only	O
of	O
insulin	B
but	O
also	O
of	O
glucagon	O
and	O
glucose	O
levels	O

In	O
contrast	O
,	O
nanogram	O
amounts	O
of	O
oxytocin	B
administered	O
ICV	O
cause	O
a	O
rise	O
of	O
insulin	B
levels	O

The	O
responses	O
of	O
serum	O
oxytocin	B
(	O
OT	O
)	O
and	O
vasopressin	O
(	O
AVP	O
)	O
to	O
the	O
serotonergic	O
HT1A	O
agonist	O
buspirone	O
(	O
15	O
mg	O
p.o	O
.	O
)	O
or	O
the	O
HTD1	O
agonist	O
sumatriptan	O
(	O
6	O
mg	O
injected	O
subcutaneously	O
)	O
were	O
evaluated	O
in	O
7	O
normal	O
men	O
either	O
in	O
basal	O
conditions	O
or	O
during	O
an	O
insulin	B
(	O
0.15	O
iu	O
/	O
kg	O
as	O
an	O
i.v	O
.	O
bolus	O
)	O
tolerance	O
test	O
(	O
ITT	O
)	O

Stimulation	O
of	O
5HT-1D	O
receptors	O
with	O
sumatriptan	O
was	O
unable	O
to	O
change	O
neither	O
AVP	O
nor	O
OT	B
response	O
to	O
insulin	B
-	O
induced	O
hypoglycemia	O

Inositol	B
1,4,5-trisphosphate	I
and	O
oxytocin	B
binding	O
in	O
human	O
myometrium	O

The	O
influence	O
of	O
myrigalone	O
B	O
,	O
a	O
flavonoid	B
from	O
the	O
fruit	O
exudate	O
of	O
Myrica	O
gale	O
L.	O
on	O
Cu	O
(	O
2+	O
)	O
-induced	O
oxidation	O
of	O
low	O
density	O
lipoprotein	O
from	O
cholesterol	B
fed	O
rabbits	O
was	O
investigated	O

Gamma	O
-	O
aminobutyric	O
acid	O
mediation	O
of	O
the	O
inhibitory	O
effect	O
of	O
nitric	O
oxide	O
on	O
the	O
arginine	O
vasopressin	O
and	O
oxytocin	B
responses	O
to	O
insulin	B
-	O
induced	O
hypoglycemia	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
nitric	O
oxide	O
(	O
NO	O
)	O
synthase	O
inhibitor	O
L	O
-	O
NAME	O
exerts	O
positive	O
effects	O
on	O
the	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
and	O
oxytocin	B
(	O
OT	O
)	O
responses	O
to	O
insulin	B
-	O
induced	O
hypoglycemia	O
,	O
suggesting	O
inhibitory	O
actions	O
of	O
NO	O

AVP	O
and	O
OT	B
secretory	O
patterns	O
during	O
insulin	B
(	O
0.15	O
IU	O
/	O
kg	O
,	O
i.v.	O
)	O
-tolerance	O
tests	O
(	O
ITT	O
)	O
were	O
examined	O
in	O
seven	O
normal	O
male	O
subjects	O
with	O
(	O
experimental	O
tests	O
)	O
and	O
without	O
(	O
control	O
test	O
)	O
concomitant	O
treatment	O
with	O
L	O
-	O
NAME	O
(	O
40	O
micrograms	O
/	O
kg	O
injected	O
plus	O
50	O
micrograms	O
/	O
kg	O
infused	O
,	O
i.v	O
.	O
)	O
,	O
the	O
GABAergic	O
agent	O
sodium	O
valproate	O
(	O
600	O
mg	O
in	O
three	O
divided	O
doses	O
orally	O
)	O
or	O
the	O
combination	O
of	O
L	O
-	O
NAME	O
and	O
sodium	O
valproate	O

Insulin	B
-	O
induced	O
hypoglycemia	O
increased	O
by	O
2-fold	O
(	O
peak	O
vs.	O
baseline	O
)	O
plasma	O
AVP	O
and	O
OT	B
levels	O

These	O
data	O
indicate	O
a	O
GABAergic	O
mediation	O
of	O
the	O
inhibitory	O
modulation	O
by	O
NO	O
of	O
the	O
AVP	O
and	O
OT	B
responses	O
to	O
insulin	B
-	O
induced	O
hypoglycemia	O

Correlation	O
between	O
the	O
stimulatory	O
effect	O
of	O
oxytocin	B
on	O
the	O
formation	O
of	O
inositol	B
phosphates	I
and	O
the	O
oxytocin	O
receptor	O
level	O
in	O
the	O
pregnant	O
rabbit	O
myometrium	O

OBJECTIVE	O
:	O
In	O
order	O
to	O
elucidate	O
the	O
roles	O
of	O
inositol	B
trisphosphate	I
(	O
IP3	O
)	O
and	O
oxytocin	O
(	O
OT	O
)	O
receptors	O
in	O
rabbit	O
parturition	O
,	O
the	O
concentration	O
of	O
IP3	B
induced	O
by	O
OT	B
and	O
the	O
OT	O
receptor	O
levels	O
were	O
determined	O
in	O
rabbit	O
myometria	O
before	O
and	O
after	O
parturition	O

METHODS	O
:	O
The	O
effects	O
of	O
OT	B
on	O
IP3	B
formation	O
and	O
OT	O
receptor	O
levels	O
were	O
determined	O
in	O
the	O
myometria	O
of	O
non	O
-	O
pregnant	O
rabbits	O
,	O
Days	O
26	O
,	O
28	O
and	O
30	O
of	O
pregnancy	O
rabbits	O
,	O
postpartum	O
rabbits	O
within	O
12	O
hours	O
and	O
steroid	O
-	O
treated	O
ovariectomized	O
rabbits	O

RESULTS	O
:	O
OT	O
receptors	O
were	O
not	O
detectable	O
in	O
the	O
myometria	O
of	O
non	O
-	O
pregnant	O
rabbits	O
,	O
and	O
OT	B
had	O
no	O
effect	O
on	O
the	O
formation	O
of	O
inositol	B
phosphates	I
(	O
IPs	O
)	O

On	O
Day	O
28	O
of	O
pregnancy	O
,	O
OT	O
receptors	O
became	O
detectable	O
,	O
and	O
then	O
OT	B
could	O
induce	O
the	O
formation	O
of	O
IPs	B

Thereafter	O
,	O
the	O
stimulatory	O
effects	O
of	O
OT	B
on	O
IPs	B
formation	O
and	O
the	O
OT	O
receptor	O
levels	O
dramatically	O
increased	O
toward	O
the	O
end	O
of	O
pregnancy	O
and	O
reduced	O
rapidly	O
after	O
parturition	O

When	O
the	O
ovariectomized	O
pregnant	O
rabbits	O
were	O
treated	O
with	O
estrogen	O
,	O
OT	O
receptors	O
in	O
the	O
myometrium	O
were	O
induced	O
,	O
and	O
OT	B
acquired	O
the	O
ability	O
to	O
stimulate	O
IP3	B
formation	O

In	O
addition	O
,	O
an	O
OT	O
receptor	O
antagonist	O
inhibited	O
the	O
stimulatory	O
effects	O
of	O
OT	B
on	O
IP3	B
formation	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
the	O
formation	O
of	O
IPs	B
by	O
OT	B
,	O
the	O
OT	O
receptor	O
levels	O
in	O
the	O
myometrium	O
,	O
and	O
the	O
production	O
of	O
PGF2	O
in	O
the	O
decidua	O
might	O
play	O
crucial	O
roles	O
in	O
parturition	O

Immunohistochemical	O
localization	O
of	O
leptin	B
and	O
uncoupling	B
protein	I
in	O
white	O
and	O
brown	O
adipose	O
tissue	O

To	O
establish	O
the	O
cell	O
type	O
expressing	O
leptin	B
,	O
we	O
also	O
assessed	O
the	O
size	O
and	O
organization	O
of	O
lipid	O
droplets	O
,	O
the	O
ultrastructural	O
features	O
of	O
mitochondria	O
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
uncoupling	B
protein	I
,	O
a	O
brown	O
fat	O
-	O
specific	O
marker	O

In	O
brown	O
adipose	O
tissue	O
of	O
lean	O
animals	O
,	O
multilocular	O
uncoupling	B
protein	I
(	O
UCP	O
)	O
-positive	O
brown	O
adipocytes	O
had	O
typical	O
brown	O
mitochondria	O
and	O
were	O
leptin	B
-	O
negative	O
,	O
both	O
in	O
fed	O
and	O
fasted	O
conditions	O

At	O
the	O
periphery	O
of	O
the	O
interscapular	O
brown	O
adipose	O
tissue	O
depot	O
,	O
unilocular	O
,	O
UCP	B
-	O
negative	O
adipocytes	O
(	O
mean	O
diameter	O
:	O
41.55	O
microns	O
)	O
with	O
white	O
-	O
type	O
mitochondria	O
were	O
observed	O
,	O
and	O
these	O
cells	O
were	O
leptin	B
-	O
positive	O

In	O
obese	O
(	O
db	O
/	O
db	O
)	O
animals	O
,	O
brown	O
fat	O
was	O
composed	O
mainly	O
of	O
small	O
unilocular	O
,	O
UCP	B
-	O
positive	O
adipocytes	O
(	O
mean	O
diameter	O
:	O
40.08	O
microns	O
)	O
,	O
which	O
were	O
also	O
leptin	B
-	O
positive	O

In	O
summary	O
,	O
classical	O
brown	O
adipocytes	O
differ	O
from	O
white	O
adipocytes	O
,	O
not	O
only	O
by	O
their	O
morphology	O
and	O
UCP	B
expression	O
,	O
but	O
also	O
by	O
their	O
apparent	O
lack	O
of	O
detectable	O
leptin	B
expression	O

Oxytocin	B
(	O
OT	O
)	O
and	O
vasopressin	O
(	O
AVP	O
)	O
stimulate	O
insulin	B
and	O
glucagon	O
release	O
from	O
the	O
pancreas	O
,	O
and	O
evoke	O
insulin	B
secretion	O
from	O
the	O
rat	O
insulinoma	O
cell	O
line	O
,	O
RINm5F	O

These	O
findings	O
support	O
the	O
concept	O
that	O
the	O
mitochondrial	O
metabolism	O
of	O
nutrient	O
molecules	O
is	O
an	O
event	O
sufficient	O
to	O
acutely	O
augment	O
insulin	B
release	O
from	O
the	O
beta	O
cell	O
,	O
to	O
increase	O
phospholipase	B
C	I
-	O
mediated	O
phosphoinositide	O
hydrolysis	O
,	O
and	O
to	O
induce	O
time	O
-	O
dependent	O
potentiation	O
of	O
insulin	B
secretion	O

Homogeneous	O
liposome	O
immunoassay	O
for	O
insulin	B
using	O
phospholipase	B
C	I
from	O
Clostridium	O
perfringens	O

Insulin	B
was	O
conjugated	O
to	O
phospholipase	B
C	I
by	O
a	O
three	O
-	O
step	O
procedure	O
with	O
hetero	O
-	O
bifunctional	O
crosslinking	O
reagents	O
,	O
succinimidyl	O
4-	O
(	O
N	O
-	O
maleimidomethyl	O
)	O
cyclohexane-1-carboxylate	O
and	O
3-	O
(	O
2-pyridyldithio	O
)	O
propionic	O
acid	O
N	O
-	O
hydroxysuccinimide	O
ester	O

Both	O
p	O
-	O
nitrophenylphosphatidylcholine	O
hydrolytic	O
activity	O
and	O
liposome	O
lytic	O
activity	O
of	O
insulin	B
-	O
phospholipase	B
C	I
conjugate	O
were	O
inhibited	O
in	O
the	O
presence	O
of	O
insulin	B
antiserum	O

The	O
effects	O
of	O
prostaglandin	O
F2	O
alpha	O
(	O
PGF2	O
alpha	O
)	O
on	O
intracellular	O
Ca2	O
+	O
concentration	O
(	O
[	O
Ca2+	O
]	O
i	O
)	O
and	O
inositol	B
phosphate	I
(	O
IP	O
)	O
generation	O
in	O
human	O
myometrial	O
cells	O
were	O
evaluated	O
and	O
compared	O
to	O
the	O
effects	O
of	O
oxytocin	B

In	O
contrast	O
,	O
the	O
potencies	O
of	O
oxytocin	B
to	O
raise	O
IP	B
and	O
[	O
Ca2+	O
]	O
i	O
were	O
similar	O
and	O
independent	O
of	O
extracellular	O
Ca2	O
+	O
,	O
and	O
could	O
be	O
suppressed	O
by	O
pertussis	O
toxin	O
and	O
phorbol	O
ester	O
,	O
but	O
not	O
by	O
verapamil	O

The	O
action	O
of	O
PGF2	O
alpha	O
depends	O
on	O
extracellular	O
Ca2	O
+	O
,	O
whereas	O
oxytocin	B
activates	O
the	O
G	O
-	O
protein	O
-	O
dependent	O
phospholipase	O
-	O
C	O
-	O
IP3-Ca2	B
+	O
signal	O
-	O
transducing	O
pathway	O
,	O
complemented	O
by	O
the	O
influx	O
of	O
extracellular	O
Ca2	O
+	O

Roles	O
of	O
GTP	O
and	O
phospholipase	B
C	I
in	O
the	O
potentiation	O
of	O
Ca	O
(	O
2+	O
)	O
-induced	O
insulin	B
secretion	O
by	O
glucose	O
in	O
rat	O
pancreatic	O
islets	O

There	O
was	O
a	O
98	O
%	O
greater	O
augmentation	O
of	O
insulin	B
secretion	O
by	O
16.7	O
mM	O
glucose	O
(	O
in	O
the	O
presence	O
of	O
diazoxide	O
and	O
40	O
mM	O
K+	O
)	O
in	O
primed	O
islets	O
;	O
however	O
,	O
the	O
ability	O
of	O
high	O
glucose	O
to	O
augment	O
PLC	B
activity	O
bore	O
no	O
relationship	O
to	O
the	O
secretory	O
response	O

MPA	O
markedly	O
inhibited	O
PLC	B
in	O
both	O
conditions	O
;	O
however	O
,	O
insulin	B
secretion	O
was	O
only	O
inhibited	O
(	O
by	O
46	O
%	O
)	O
in	O
primed	O
islets	O

These	O
data	O
indicate	O
that	O
an	O
adequate	O
level	O
of	O
GTP	O
is	O
critical	O
for	O
glucose	O
's	O
potentiation	O
of	O
Ca	O
(	O
2+	O
)	O
-induced	O
insulin	B
secretion	O
in	O
primed	O
islets	O
but	O
that	O
PLC	B
activation	O
can	O
clearly	O
be	O
dissociated	O
from	O
insulin	B
secretion	O
and	O
therefore	O
can	O
not	O
be	O
the	O
major	O
cause	O
of	O
glucose	O
's	O
augmentation	O
of	O
Ca	O
(	O
2+	O
)	O
-induced	O
insulin	B
secretion	O

Regulation	O
of	O
insulin	B
secretion	O
via	O
ATP	O
-	O
sensitive	O
K+	O
channel	O
independent	O
mechanisms	O
:	O
role	O
of	O
phospholipase	B
C	I

The	O
further	O
addition	O
of	O
carbachol	O
,	O
an	O
agonist	O
that	O
activates	O
an	O
isozyme	O
of	O
phospholipase	B
C	I
distinct	O
from	O
that	O
activated	O
by	O
glucose	O
,	O
together	O
with	O
K+	O
,	O
20	O
mM	O
glucose	O
,	O
plus	O
diazoxide	O
resulted	O
in	O
a	O
sustained	O
amplification	O
of	O
insulin	B
secretion	O
from	O
mouse	O
but	O
not	O
rat	O
islets	O

The	O
inability	O
to	O
activate	O
a	O
nutrient-	O
and	O
calcium	O
-	O
regulated	O
phospholipase	B
C	I
isozyme	O
in	O
mouse	O
islets	O
to	O
the	O
same	O
extent	O
as	O
in	O
rat	O
islets	O
appears	O
to	O
account	O
,	O
at	O
least	O
in	O
part	O
,	O
for	O
these	O
different	O
insulin	B
secretory	O
responses	O
under	O
these	O
unique	O
conditions	O

Signal	O
transduction	O
in	O
pancreatic	O
beta	O
-	O
cells	O
:	O
Regulation	O
of	O
insulin	B
secretion	O
by	O
information	O
flow	O
in	O
the	O
phospholipase	B
C	I
/	O
Protein	O
kinase	O
C	O
pathway	O

The	O
physiologic	O
regulation	O
of	O
glucose	O
-	O
induced	O
insulin	B
secretion	O
is	O
dependent	O
upon	O
the	O
activation	O
of	O
information	O
flow	O
in	O
the	O
phospholipase	B
C	I
(	O
PLC	O
)	O
/	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
signal	O
transduction	O
system	O

When	O
rat	O
islet	O
are	O
cultured	O
for	O
short	O
periods	O
,	O
the	O
content	O
and	O
activation	O
of	O
PLC	B
in	O
response	O
to	O
glucose	O
decreases	O
and	O
this	O
biochemical	O
defect	O
in	O
signal	O
transduction	O
is	O
paralleled	O
by	O
significant	O
reductions	O
in	O
glucose	O
-	O
induced	O
insulin	B
secretion	O

Biphasic	O
insulin	B
secretion	O
can	O
be	O
evoked	O
and	O
time	O
-	O
dependent	O
potentiation	O
can	O
be	O
induced	O
in	O
mouse	O
islets	O
by	O
carbachol	O
,	O
an	O
agonist	O
that	O
activates	O
an	O
isozyme	O
of	O
PLC	B
distinct	O
from	O
that	O
activated	O
by	O
glucose	O

When	O
taken	O
in	O
their	O
entirety	O
,	O
the	O
experimental	O
evidence	O
suggests	O
that	O
the	O
activation	O
of	O
PLC	B
is	O
an	O
essential	O
component	O
in	O
the	O
physiologic	O
regulation	O
of	O
insulin	B
secretion	O
and	O
that	O
disordered	O
activation	O
of	O
the	O
enzyme	O
culminates	O
in	O
disordered	O
insulin	B
release	O

Cellular	O
preincubation	O
with	O
200	O
microg	O
/	O
ml	O
antibodies	O
against	O
the	O
inositolphosphoglycan	O
(	O
IPG	O
)	O
moiety	O
of	O
the	O
GPI	O
-	O
anchor	O
(	O
Ab	O
(	O
IPG	O
)	O
)	O
,	O
or	O
depletion	O
in	O
GPI	O
-	O
anchored	O
proteins	O
by	O
cellular	O
pretreatment	O
with	O
0.5	O
U	O
/	O
ml	O
PI	O
-	O
PLC	B
,	O
1	O
mM	O
insulin	B
and	O
2	O
HU	O
/	O
ml	O
streptolysin	O
-	O
O	O
,	O
or	O
depletion	O
in	O
membrane	O
cholesterol	O
content	O
by	O
filipin	O
(	O
5	O
microg	O
/	O
ml	O
)	O
,	O
digitonin	O
(	O
5	O
microg	O
/	O
ml	O
)	O
and	O
cholesterol	O
oxidase	O
(	O
0.5	O
U	O
/	O
ml	O
)	O
decreases	O
the	O
HDL3-signal	O
,	O
suggesting	O
the	O
involvement	O
of	O
a	O
lipolytic	O
cleavage	O
of	O
GPI	O
-	O
anchored	O
proteins	O

Amyloid	B
beta	O
protein	O
(	O
25	O
-	O
35	O
)	O
stimulation	O
of	O
phospholipase	B
C	I
in	O
LA	O
-	O
N-2	O
cells	O

This	O
phospholipase	B
C	I
stimulation	O
by	O
amyloid	B
beta	O
protein	O
appeared	O
to	O
be	O
pertussis	O
toxin	O
sensitive	O

It	O
is	O
possible	O
that	O
this	O
phospholipase	B
C	I
stimulation	O
by	O
amyloid	B
beta	O
protein	O
is	O
a	O
receptor	O
-	O
mediated	O
process	O

Amyloid	B
beta	O
protein	O
stimulation	O
of	O
phospholipase	B
C	I
was	O
absent	O
from	O
LA	O
-	O
N-2	O
cells	O
previously	O
treated	O
with	O
norepinephrine	O
,	O
trans-1-amino-1,3-cyclopentanedicarboxylic	O
acid	O
(	O
t	O
-	O
ACPD	O
)	O
,	O
bombesin	O
,	O
or	O
amyloid	B
beta	O
peptide	O

It	O
is	O
suggested	O
that	O
this	O
observed	O
amyloid	B
beta	O
protein	O
stimulation	O
of	O
phospholipase	B
C	I
may	O
be	O
responsible	O
for	O
the	O
elevated	O
quantity	O
of	O
inositol	O
seen	O
in	O
the	O
brains	O
of	O
Alzheimer	O
's	O
disease	O
patients	O

Effects	O
of	O
oxytocin	B
,	O
arginine	O
-	O
vasopressin	O
and	O
lysine	O
-	O
vasopressin	O
on	O
insulin	B
and	O
glucagon	O
secretion	O
in	O
sheep	O

The	O
effects	O
of	O
the	O
posterior	O
-	O
pituitary	O
peptides	O
oxytocin	B
(	O
OT	O
)	O
,	O
arginine	O
-	O
vasopressin	O
(	O
AVP	O
)	O
and	O
lysine	O
-	O
vasopressin	O
(	O
LVP	O
)	O
on	O
insulin	B
and	O
glucagon	O
secretion	O
were	O
examined	O
in	O
adult	O
sheep	O

The	O
maximal	O
insulin	B
responses	O
induced	O
by	O
OT	B
and	O
AVP	O
were	O
very	O
similar	O
,	O
but	O
the	O
threshold	O
and	O
maximal	O
doses	O
of	O
AVP	O
for	O
increasing	O
plasma	O
insulin	B
were	O
higher	O
than	O
those	O
of	O
OT	B

Leptin	B
increases	O
uncoupling	B
protein	I
expression	O
and	O
energy	O
expenditure	O

Leptin	B
increased	O
BAT	O
UCP	B
mRNA	O
levels	O
greater	O
than	O
twofold	O
in	O
both	O
ad	O
libitum	O
-	O
fed	O
and	O
food	O
-	O
restricted	O
rats	O

These	O
data	O
demonstrate	O
a	O
leptin	B
-	O
induced	O
increase	O
in	O
energy	O
expenditure	O
in	O
nonmutant	O
rodents	O
and	O
suggest	O
that	O
one	O
mechanism	O
by	O
which	O
leptin	B
increases	O
energy	O
expenditure	O
is	O
through	O
increased	O
thermogenesis	O
in	O
BAT	O
,	O
including	O
increased	O
expression	O
of	O
UCP	B

Leptin	B
upregulates	O
the	O
expression	O
of	O
uncoupling	B
protein-2	I
(	O
UCP-2	O
)	O
mRNA	O
in	O
islets	O
of	O
normal	O
rats	O
,	O
but	O
has	O
no	O
effect	O
in	O
islets	O
of	O
obese	O
Zucker	O
Diabetic	O
Fatty	O
(	O
ZDF	O
)	O
rats	O
with	O
mutated	O
leptin	O
receptors	O

Oxytocin	B
-	O
stimulated	O
inositol	B
phosphate	I
turnover	O
in	O
endometrium	O
of	O
ewes	O
is	O
influenced	O
by	O
stage	O
of	O
the	O
estrous	O
cycle	O
,	O
pregnancy	O
,	O
and	O
intrauterine	O
infusion	O
of	O
ovine	O
conceptus	O
secretory	O
proteins	O

Three	O
experiments	O
(	O
Exp	O
)	O
assessed	O
the	O
influence	O
of	O
stage	O
of	O
the	O
estrous	O
cycle	O
,	O
pregnancy	O
,	O
and	O
intrauterine	O
infusion	O
of	O
ovine	O
conceptus	O
secretory	O
proteins	O
(	O
oCSP	O
)	O
on	O
turnover	O
of	O
inositol	B
trisphosphate	I
(	O
the	O
putative	O
second	O
-	O
messenger	O
for	O
oxytocin	B
-	O
stimulated	O
secretion	O
of	O
prostaglandin	O
F2	O
alpha	O
)	O
in	O
ovine	O
endometrium	O
during	O
luteolysis	O
and	O
maternal	O
recognition	O
of	O
pregnancy	O

For	O
each	O
Exp	O
,	O
100	O
mg	O
endometrium	O
was	O
incubated	O
,	O
in	O
duplicate	O
,	O
for	O
2	O
h	O
with	O
10	O
microCi	O
[	O
3H	O
]	O
inositol	O
and	O
treated	O
with	O
0	O
or	O
100	O
nM	O
oxytocin	B
(	O
OT	O
)	O
for	O
20	O
min	O
,	O
then	O
[	O
3H	O
]	O
inositol	O
mono-	O
,	O
bis-	O
,	O
and	O
trisphosphates	O
(	O
IP1	O
,	O
IP2	O
,	O
and	O
IP3	B
,	O
respectively	O
)	O
were	O
quantified	O

Insulin	B
secretion	O
is	O
regulated	O
by	O
changes	O
in	O
blood	O
glucose	O
,	O
as	O
well	O
as	O
by	O
peptides	O
from	O
the	O
gastrointestinal	O
tract	O
and	O
neurotransmitters	O
that	O
activate	O
the	O
pancreatic	O
islet	O
adenylyl	O
cyclase	O
(	O
e.g.	O
,	O
glucagon	O
-	O
like	O
peptide-1	O
)	O
and	O
phospholipase	B
C	I
(	O
PLC	O
)	O
(	O
e.g.	O
,	O
acetylcholine	O
)	O
signaling	O
pathways	O
to	O
further	O
potentiate	O
glucose	O
-	O
induced	O
insulin	B
secretion	O

However	O
,	O
leptin	O
did	O
constrain	O
the	O
enhanced	O
PLC	B
-	O
mediated	O
insulin	B
secretion	O
characteristic	O
of	O
islets	O
from	O
ob	O
/	O
ob	O
mice	O
,	O
without	O
influencing	O
release	O
from	O
islets	O
of	O
lean	O
mice	O

A	O
specific	O
enhancement	O
in	O
PLC	B
-	O
mediated	O
insulin	B
secretion	O
is	O
the	O
earliest	O
reported	O
developmental	O
alteration	O
in	O
insulin	B
secretion	O
from	O
islets	O
of	O
ob	O
/	O
ob	O
mice	O
,	O
and	O
thus	O
a	O
logical	O
target	O
for	O
leptin	O
action	O

This	O
action	O
of	O
leptin	O
on	O
PLC	B
-	O
mediated	O
insulin	B
secretion	O
was	O
dose	O
-	O
dependent	O
,	O
rapid	O
-	O
onset	O
(	O
i.e.	O
,	O
within	O
3	O
min	O
)	O
,	O
and	O
reversible	O

Leptin	O
was	O
equally	O
effective	O
in	O
constraining	O
the	O
enhanced	O
insulin	B
release	O
from	O
islets	O
of	O
ob	O
/	O
ob	O
mice	O
caused	O
by	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activation	O
,	O
a	O
downstream	O
mediator	O
of	O
the	O
PLC	B
signal	O
pathway	O

One	O
function	O
of	O
leptin	O
in	O
control	O
of	O
body	O
composition	O
is	O
thus	O
to	O
target	O
a	O
PKC	O
-	O
regulated	O
component	O
of	O
the	O
PLC	B
-	O
PKC	O
signaling	O
system	O
within	O
islets	O
to	O
prevent	O
hypersecretion	O
of	O
insulin	B

Insulin	B
stimulates	O
the	O
release	O
of	O
the	O
glycosyl	O
phosphatidylinositol	O
-	O
anchored	O
membrane	O
dipeptidase	O
from	O
3T3-L1	O
adipocytes	O
through	O
the	O
action	O
of	O
a	O
phospholipase	B
C	I

The	O
hydrophilic	O
form	O
of	O
MDP	O
released	O
from	O
the	O
cells	O
on	O
stimulation	O
with	O
insulin	B
was	O
recognized	O
by	O
antibodies	O
against	O
the	O
inositol	O
1,2-cyclic	O
monophosphate	O
cross	O
-	O
reacting	O
determinant	O
,	O
indicating	O
that	O
it	O
had	O
been	O
generated	O
by	O
cleavage	O
of	O
its	O
GPI	O
anchor	O
through	O
the	O
action	O
of	O
a	O
phospholipase	B
C	I

Interleukin-1	O
beta	O
inhibits	O
phospholipase	B
C	I
and	O
insulin	B
secretion	O
at	O
sites	O
apart	O
from	O
KATP	O
channel	O

Surprisingly	O
,	O
however	O
,	O
when	O
islets	O
were	O
depolarized	O
directly	O
using	O
either	O
of	O
two	O
agonists	O
,	O
glyburide	O
(	O
which	O
does	O
not	O
act	O
via	O
generation	O
of	O
purine	O
nucleotides	O
)	O
or	O
40	O
mM	O
K+	O
(	O
which	O
acts	O
distal	O
to	O
KATP	O
channel	O
)	O
,	O
PLC	B
and	O
insulin	B
secretion	O
were	O
again	O
obliterated	O
by	O
IL-1	O
beta	O

These	O
data	O
(	O
together	O
with	O
the	O
finding	O
that	O
IL-1	O
beta	O
inhibited	O
Ca	O
(	O
2+	O
)	O
-induced	O
insulin	B
release	O
)	O
suggest	O
that	O
,	O
in	O
addition	O
to	O
its	O
effects	O
on	O
ATP	O
synthesis	O
and	O
thereby	O
on	O
the	O
KATP	O
channel	O
,	O
IL-1	O
beta	O
has	O
at	O
least	O
two	O
undescribed	O
,	O
distal	O
effects	O
to	O
block	O
both	O
PLC	B
as	O
well	O
as	O
Ca	O
(	O
2+	O
)	O
-induced	O
exocytosis	O

Activation	O
of	O
EGFR	O
overexpressing	O
3T3-L1	O
adipocytes	O
leads	O
to	O
a	O
3.4	O
+	O
/-	O
1.2-fold	O
stimulation	O
of	O
PLC	B
activity	O
over	O
basal	O
levels	O
vs.	O
only	O
1.06	O
+	O
/-	O
0.01-fold	O
stimulation	O
by	O
insulin	B
.	O

Despite	O
the	O
low	O
levels	O
of	O
insulin	B
-	O
induced	O
PLC	B
activity	O
,	O
insulin	B
-	O
stimulated	O
glucose	O
transport	O
activity	O
was	O
similarly	O
inhibited	O
by	O
U73122	O
(	O
55.9	O
+	O
/-	O
13.1	O
%	O
inhibition	O
)	O

Inhibition	O
of	O
PLC	B
activation	O
did	O
not	O
impair	O
either	O
EGF-	O
or	O
insulin	B
-	O
induced	O
activation	O
of	O
glycogen	O
synthase	O
or	O
incorporation	O
of	O
glucose	O
into	O
lipid	O
,	O
supporting	O
the	O
hypothesis	O
that	O
both	O
EGF-	O
and	O
insulin	B
-	O
induced	O
glucose	O
disposal	O
can	O
be	O
independent	O
of	O
GLUT4-mediated	O
glucose	O
transport	O
.	O

The	O
diminution	O
of	O
glucose	O
transport	O
secondary	O
to	O
inhibition	O
of	O
PLC	B
activity	O
was	O
reflected	O
by	O
a	O
decrease	O
in	O
GLUT4	O
translocation	O
to	O
the	O
plasma	O
membrane	O
upon	O
either	O
EGF	O
or	O
insulin	B
stimulation	O

We	O
have	O
recently	O
shown	O
that	O
AVP	B
causes	O
a	O
protein	B
kinase	I
C	I
(	O
PKC	O
)	O
-dependent	O
increase	O
in	O
ACTH	O
release	O
and	O
biosynthesis	O
in	O
ovine	O
anterior	O
pituitary	O
cells	O

In	O
these	O
cells	O
,	O
AVP	B
also	O
causes	O
the	O
translocation	O
of	O
PKC	B
from	O
the	O
cytosol	O
to	O
the	O
cell	O
membrane	O
which	O
is	O
maximal	O
at	O
5	O
min	O
,	O
but	O
the	O
intracellular	O
events	O
distal	O
to	O
protein	B
kinase	I
C	I
activation	O
that	O
underlie	O
ACTH	O
secretion	O
have	O
not	O
been	O
well	O
characterized	O
to	O
date	O

Since	O
the	O
MARCKS	O
protein	O
has	O
been	O
implicated	O
in	O
neurosecretion	O
and	O
is	O
phosphorylated	O
by	O
PKC	B
in	O
synaptosomes	O
,	O
studies	O
were	O
carried	O
out	O
to	O
determine	O
whether	O
AVP	B
might	O
cause	O
MARCKS	O
phosphorylation	O
in	O
the	O
ovine	O
anterior	O
pituitary	O
,	O
and	O
to	O
determine	O
whether	O
this	O
phenomenon	O
might	O
be	O
temporally	O
correlated	O
with	O
PKC	B
translocation	O
and	O
the	O
release	O
of	O
ACTH	O

We	O
conclude	O
that	O
:	O
(	O
1	O
)	O
AVP	B
causes	O
a	O
rapid	O
,	O
and	O
reversible	O
,	O
phosphorylation	O
of	O
the	O
MARCKS	O
protein	O
in	O
the	O
ovine	O
anterior	O
pituitary	O
;	O
(	O
2	O
)	O
since	O
the	O
AVP	B
-	O
induced	O
increase	O
in	O
MARCKS	O
phosphorylation	O
occurs	O
much	O
earlier	O
in	O
these	O
cells	O
than	O
does	O
PKC	B
trans	O
-	O
location	O
,	O
MARCKS	O
phosphorylation	O
may	O
provide	O
a	O
more	O
sensitive	O
index	O
of	O
the	O
onset	O
of	O
PKC	B
activation	O
than	O
the	O
translocation	O
assay	O
;	O
(	O
3	O
)	O
the	O
close	O
temporal	O
association	O
between	O
MARCKS	O
phosphorylation	O
and	O
the	O
rapid	O
early	O
release	O
of	O
ACTH	O
suggests	O
that	O
MARCKS	O
phosphorylation	O
may	O
be	O
involved	O
in	O
the	O
initial	O
intracellular	O
events	O
that	O
underly	O
exocytosis	O
of	O
the	O
hormone	O
.	O

PKB	O
,	O
which	O
is	O
an	O
important	O
early	O
PI	O
3-kinase	O
-	O
dependent	O
component	O
of	O
insulin	B
signalling	O
pathways	O
,	O
is	O
also	O
down	O
-	O
regulated	O
by	O
PLC	B
-	O
coupled	O
agonists	O

Oxytocin	B
-	O
treated	O
male	O
rats	O
had	O
increased	O
circulating	O
levels	O
of	O
cholecystokinin	O
,	O
a	O
tendency	O
to	O
increased	O
plasma	O
levels	O
of	O
insulin	B
(	O
p	O
=	O
0.066	O
)	O
,	O
and	O
relatively	O
more	O
adipose	O
tissue	O
in	O
the	O
thigh	O
and	O
interscapular	O
region	O
,	O
compared	O
with	O
controls	O

However	O
,	O
in	O
brown	O
fat	O
,	O
we	O
observed	O
a	O
2	O
-	O
3-fold	O
increase	O
in	O
the	O
expression	O
of	O
UCP1	B
in	O
response	O
to	O
dietary	O
fat	O
challenge	O
,	O
which	O
may	O
be	O
related	O
to	O
diet	O
-	O
induced	O
elevations	O
in	O
plasma	O
leptin	B
levels	O

Similarly	O
,	O
carbachol	O
,	O
but	O
not	O
AVP	B
or	O
DDAVP	O
,	O
induced	O
a	O
significant	O
increase	O
in	O
membrane	O
-	O
associated	O
protein	B
kinase	I
C	I
(	O
PKC	O
)	O
enzyme	O
activity	O

In	O
contrast	O
,	O
AVP	B
had	O
no	O
effect	O
on	O
the	O
distribution	O
of	O
any	O
PKC	B
isoform	O
tested	O

Vasopressin	B
-	O
induced	O
activation	O
of	O
protein	B
kinase	I
C	I
in	O
renal	O
epithelial	O
cells	O

AVP	B
induced	O
a	O
biphasic	O
increase	O
in	O
diacylglycerol	O
generation	O
,	O
characterized	O
by	O
an	O
initial	O
rapid	O
rise	O
and	O
then	O
a	O
sustained	O
elevation	O
,	O
and	O
PKC	B
activation	O
,	O
reflected	O
by	O
phosphorylation	O
of	O
a	O
specific	O
80	O
kDa	O
myristoylated	O
alanine	O
-	O
rich	O
PKC	O
substrate	O
(	O
MARCKS	O
)	O

These	O
results	O
argue	O
that	O
Ca	O
(	O
2+	O
)	O
-dependent	O
PKC	B
is	O
involved	O
in	O
the	O
action	O
of	O
AVP	B
,	O
and	O
that	O
of	O
other	O
agonists	O
,	O
which	O
stimulate	O
sodium	O
transport	O

Inhibition	O
of	O
5-HT3	O
serotonergic	O
receptors	O
with	O
ondansetron	O
(	O
4	O
or	O
8	O
mg	O
)	O
did	O
not	O
modify	O
the	O
basal	O
secretion	O
of	O
AVP	O
and	O
OT	B
and	O
the	O
OT	B
response	O
to	O
insulin	B
-	O
induced	O
hypoglycemia	O

Treatment	O
with	O
(	O
+	O
)	O
-trifluoro	O
-	O
ABA	O
strongly	O
inhibited	O
the	O
gibberellic	B
acid	I
-	O
inducible	O
expression	O
of	O
alpha	B
-	I
amylase	I
I-1	O
encoded	O
by	O
RAmy1A	O
in	O
the	O
aleurone	O
layers	O
of	O
embryoless	O
half	O
-	O
seeds	O
at	O
the	O
levels	O
of	O
transcription	O
,	O
protein	O
synthesis	O
,	O
and	O
enzyme	O
activity	O

Furthermore	O
,	O
treatment	O
of	O
isolated	O
rat	O
diaphragms	O
and	O
adipocytes	O
with	O
PIG	O
-	O
P	O
as	O
well	O
as	O
with	O
other	O
agents	O
exerting	O
partially	O
insulin	B
-	O
mimetic	O
activity	O
,	O
such	O
as	O
PI	O
-	O
specific	O
phospholipase	B
C	I
(	O
PLC	O
)	O
and	O
the	O
sulfonylurea	O
glimepiride	O
,	O
triggered	O
tyrosine	O
phosphorylation	O
of	O
the	O
caveolar	O
marker	O
protein	O
caveolin	O
,	O
which	O
was	O
apparently	O
correlated	O
with	O
stimulation	O
of	O
lipogenesis	O

Strikingly	O
,	O
in	O
adipocytes	O
subjected	O
to	O
combined	O
trypsin	O
/	O
salt	O
treatment	O
,	O
PIG	O
-	O
P	O
,	O
PI	O
-	O
specific	O
PLC	B
,	O
and	O
glimepiride	O
failed	O
completely	O
to	O
provoke	O
insulin	B
-	O
mimetic	O
effects	O

Chronic	O
central	O
leptin	B
infusion	O
enhances	O
insulin	O
-	O
stimulated	O
glucose	O
metabolism	O
and	O
favors	O
the	O
expression	O
of	O
uncoupling	B
proteins	I

In	O
marked	O
contrast	O
,	O
intracerebroventricular	O
leptin	B
administration	O
was	O
accompanied	O
by	O
the	O
maintenance	O
of	O
high	O
UCP1	B
,	O
UCP2	B
,	O
and	O
UCP3	B
expression	O
in	O
all	O
these	O
tissues	O

While	O
leptin	B
maintains	O
or	O
favors	O
energy	O
-	O
dissipating	O
mechanisms	O
(	O
UCP1	B
,	O
UCP2	B
,	O
and	O
UCP3	B
)	O
,	O
the	O
latter	O
are	O
markedly	O
depressed	O
in	O
pair	O
-	O
fed	O
rats	O

Concurrent	O
decrease	O
of	O
vasopressin	B
and	O
protein	B
kinase	I
Calpha	I
immunoreactivity	O
during	O
the	O
light	O
phase	O
in	O
the	O
vole	O
suprachiasmatic	O
nucleus	O

Mean	O
numbers	O
of	O
AVP-	B
and	O
protein	B
kinase	I
Calpha	I
-	O
immunoreactive	O
neurons	O
were	O
determined	O
in	O
the	O
suprachiasmatic	O
nucleus	O
of	O
common	O
voles	O
,	O
entrained	O
to	O
a	O
12:12	O
h	O
light	O
-	O
dark	O
(	O
LD	O
)	O
cycle	O
,	O
at	O
the	O
beginning	O
of	O
the	O
light	O
period	O
(	O
zeitgeber	O
time	O
zero	O
)	O
and	O
6	O
h	O
later	O
(	O
zeitgeber	O
time	O
six	O
)	O

At	O
zeitgeber	O
time	O
zero	O
,	O
mean	O
numbers	O
of	O
AVP-	B
and	O
protein	B
kinase	I
Calpha-	I
immunoreactive	O
neurons	O
were	O
2194	O
and	O
9897	O
,	O
respectively	O

Although	O
osmotic	O
stimuli	O
cause	O
an	O
increase	O
in	O
nitric	O
oxide	O
synthase	O
(	O
NOS	O
)	O
activity	O
as	O
well	O
as	O
synthesis	O
of	O
AVP	O
and	O
oxytocin	B
in	O
the	O
paraventricular	O
(	O
PVN	O
)	O
and	O
supraoptic	O
nuclei	O
(	O
SON	O
)	O
,	O
it	O
is	O
not	O
known	O
whether	O
NOS	O
activity	O
in	O
the	O
hypothalamus	O
changes	O
in	O
the	O
diabetic	O
patients	O
who	O
have	O
plasma	O
hyperosmolality	O
with	O
hyperglycaemia	O
caused	O
by	O
insulin	B
deficiency	O

Three	O
weeks	O
after	O
administration	O
of	O
STZ	O
,	O
the	O
diabetic	O
rats	O
were	O
subcutaneously	O
treated	O
with	O
insulin	B
for	O
1	O
week	O
,	O
which	O
resulted	O
in	O
significant	O
suppression	O
of	O
the	O
induction	O
of	O
nNOS	O
,	O
AVP	O
and	O
oxytocin	B
gene	O
expression	O
in	O
the	O
PVN	O
and	O
SON	O

OT	B
evokes	O
the	O
release	O
of	O
Ca2	O
+	O
from	O
IP3-sensitive	B
intracellular	O
stores	O

To	O
explore	O
the	O
possible	O
roles	O
of	O
the	O
hypothalamic	O
melanocortin	O
system	O
in	O
leptin	B
action	O
,	O
we	O
examined	O
the	O
effects	O
of	O
intracerebroventricular	O
(	O
i.c.v	O
.	O
)	O
injection	O
of	O
leptin	B
with	O
or	O
without	O
SHU9119	O
,	O
a	O
potent	O
antagonist	O
of	O
alpha	O
-	O
melanocyte	O
stimulating	O
hormone	O
,	O
on	O
food	O
intake	O
,	O
body	O
weight	O
,	O
and	O
mitochondrial	O
uncoupling	B
protein-1	I
(	O
UCP-1	O
)	O
mRNA	O
expression	O
in	O
the	O
brown	O
adipose	O
tissue	O
(	O
BAT	O
)	O
in	O
rats	O

A	O
single	O
i.c.v	O
.	O
injection	O
of	O
leptin	B
decreased	O
cumulative	O
food	O
intake	O
and	O
body	O
weight	O
gain	O
,	O
and	O
increased	O
UCP-1	B
mRNA	O
expression	O
during	O
3	O
h	O
at	O
the	O
onset	O
of	O
the	O
dark	O
phase	O

Co	O
-	O
injection	O
of	O
SHU9119	O
also	O
inhibited	O
completely	O
the	O
leptin	B
-	O
induced	O
increase	O
in	O
UCP-1	B
mRNA	O
expression	O
in	O
the	O
BAT	O

It	O
has	O
been	O
established	O
that	O
amyloid	B
beta	O
peptide	O
(	O
AbetaP	O
)	O
activates	O
phospholipase	O
A2	O
,	O
phospholipase	B
C	I
and	O
phospholipase	O
D	O
of	O
LA	O
-	O
N-2	O
cells	O
and	O
other	O
cell	O
types	O

(	O
-	O
)	O
Nicotine	O
did	O
not	O
blunt	O
the	O
AbetaP	B
activation	O
of	O
phospholipase	B
C	I

These	O
observations	O
suggest	O
that	O
bradykinin	O
,	O
like	O
oxytocin	B
,	O
activates	O
phospholipase	O
C	O
which	O
generates	O
IP3	B
with	O
a	O
subsequent	O
release	O
of	O
Ca2	O
+	O
from	O
intracellular	O
stores	O
followed	O
by	O
store	O
-	O
operated	O
Ca2	O
+	O
influx	O

These	O
findings	O
led	O
us	O
to	O
conclude	O
that	O
inositol	O
trisphosphate	O
[	O
corrected	O
]	O
causes	O
Ca2	O
+	O
mobilization	O
by	O
muscarinic	O
activation	O
of	O
PLC	B
,	O
leading	O
to	O
intracellular	O
translocation	O
of	O
insulin	B
granules	O
to	O
the	O
ready	O
-	O
releasable	O
pool	O
in	O
pancreatic	O
beta	O
-	O
cells	O
via	O
Ca2+	O
/	O
calmodulin	O
-	O
dependent	O
phosphorylation	O
of	O
myosin	O
light	O
chains	O

To	O
elucidate	O
the	O
pathophysiologic	O
significance	O
of	O
UCP3	B
and	O
UCP2	B
in	O
the	O
effect	O
of	O
TZDs	O
on	O
glucose	O
metabolism	O
and	O
energy	O
expenditure	O
,	O
we	O
examined	O
their	O
basal	O
mRNA	O
levels	O
in	O
the	O
WAT	O
,	O
brown	O
adipose	O
tissue	O
(	O
BAT	O
)	O
,	O
and	O
skeletal	O
muscle	O
from	O
Wistar	O
fatty	O
rats	O
,	O
a	O
rat	O
model	O
of	O
NIDDM	O
and	O
obesity	O
with	O
leptin	B
receptor	O
defect	O
,	O
and	O
investigated	O
expression	O
of	O
the	O
genes	O
encoding	O
UCP3	B
and	O
UCP2	B
in	O
Wistar	O
fatty	O
rats	O
and	O
in	O
Wistar	O
lean	O
rats	O
with	O
2-week	O
oral	O
administration	O
of	O
3	O
mg	O
x	O
kg	O
(	O
-1	O
)	O
x	O
day	O
(	O
-1	O
)	O
pioglitazone	O
,	O
a	O
TZD	O
derivative	O

These	O
results	O
clearly	O
demonstrate	O
that	O
UCP3	B
gene	O
expression	O
is	O
upregulated	O
by	O
TZDs	O
in	O
the	O
WAT	O
and	O
BAT	O
in	O
Wistar	O
fatty	O
rats	O
,	O
an	O
obese	O
model	O
with	O
leptin	B
receptor	O
defect	O
,	O
and	O
that	O
adipose	O
UCP3	B
gene	O
expression	O
is	O
increased	O
in	O
response	O
to	O
TZDs	O
in	O
vitro	O

UCP2	B
,	O
UCP3	B
and	O
leptin	B
gene	O
expression	O
:	O
modulation	O
by	O
food	O
restriction	O
and	O
leptin	B

To	O
determine	O
the	O
effects	O
of	O
food	O
restriction	O
and	O
leptin	B
administration	O
on	O
several	O
transcripts	O
involved	O
in	O
energy	O
homeostasis	O
,	O
we	O
examined	O
leptin	B
,	O
uncoupling	B
proteins	I
(	O
UCP	O
)	O
1	O
,	O
2	O
and	O
3	O
,	O
lipoprotein	O
lipase	O
(	O
LPL	O
)	O
,	O
beta3-adrenergic	O
receptors	O
(	O
beta3AR	O
)	O
and	O
hormone	O
-	O
sensitive	O
lipase	O
(	O
HSL	O
)	O
mRNA	O
levels	O
in	O
brown	O
adipose	O
tissue	O
(	O
BAT	O
)	O
and	O
epididymal	O
(	O
EWAT	O
)	O
and	O
perirenal	O
(	O
PWAT	O
)	O
white	O
adipose	O
tissue	O
in	O
three	O
groups	O
of	O
rats	O

Leptin	B
increased	O
LPL	O
mRNA	O
by	O
80	O
%	O
,	O
UCP1	B
mRNA	O
twofold	O
,	O
and	O
UCP3	B
mRNA	O
levels	O
by	O
62	O
%	O
in	O
BAT	O
,	O
and	O
increased	O
UCP2	B
mRNA	O
levels	O
twofold	O
in	O
EWAT	O

The	O
present	O
study	O
indicates	O
that	O
leptin	B
increases	O
the	O
gene	O
expression	O
of	O
UCP2	B
in	O
EWAT	O
and	O
that	O
of	O
UCP1	B
,	O
UCP3	B
and	O
LPL	O
in	O
BAT	O
,	O
whereas	O
reduced	O
food	O
consumption	O
but	O
not	O
leptin	O
,	O
decreases	O
LPL	O
expression	O
in	O
WAT	O

DNase1	O
footprints	O
suggest	O
the	O
involvement	O
of	O
at	O
least	O
three	O
types	O
of	O
transcription	O
factors	O
in	O
the	O
regulation	O
of	O
alpha	B
-	I
Amy2	I
/	I
A	I
by	O
gibberellin	B

The	O
regulation	O
of	O
alpha	B
-	I
Amy2	I
genes	O
by	O
GA	B
therefore	O
involves	O
an	O
interplay	O
of	O
at	O
least	O
three	O
different	O
types	O
of	O
transcription	O
factor	O

Oxytocin	O
-	O
stimulated	O
insulin	B
release	O
in	O
a	O
clonal	O
beta	O
-	O
cell	O
line	O
RINm5F	O
:	O
involvement	O
of	O
phospholipase	B
C	I
-	O
dependent	O
and	O
-independent	O
pathways	O
.	O

CONCLUSION	O
:	O
Oxy	O
increases	O
insulin	B
release	O
through	O
both	O
PLC	B
and	O
non	O
-	O
PLC	O
mediated	O
signal	O
transduction	O
mechanisms	O
.	O

In	O
addition	O
,	O
U-73122	O
diminished	O
the	O
Oxy	B
-	O
induced	O
increase	O
in	O
intracellular	O
concentration	O
of	O
inositol	B
1	I
,	I
4	I
,	I
5-triphosphate	I
(	O
IP3	O
)	O

U-73122	O
at	O
8	O
mumol	O
.	O
L-1	O
totally	O
abolished	O
the	O
Oxy	B
-	O
induced	O
increases	O
in	O
[	O
Ca2+	O
]	O
i	O
and	O
IP3	B
;	O
however	O
it	O
reduced	O
the	O
Oxy	B
-	O
induced	O
increase	O
in	O
insulin	O
release	O
only	O
by	O
36	O
%	O
and	O
63	O
%	O
in	O
the	O
monolayer	O
and	O
suspended	O
cell	O
preparations	O
,	O
respectively	O

Oxytocin	B
-	O
stimulated	O
insulin	B
release	O
in	O
a	O
clonal	O
beta	O
-	O
cell	O
line	O
RINm5F	O
:	O
involvement	O
of	O
phospholipase	O
C	O
-	O
dependent	O
and	O
-independent	O
pathways	O

AIM	O
:	O
To	O
study	O
the	O
mechanisms	O
underlying	O
oxytocin	B
(	O
Oxy	O
)	O
-induced	O
insulin	B
release	O

RESULTS	O
:	O
Oxy	B
increased	O
insulin	B
release	O
and	O
[	O
Ca2+	O
]	O
i	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O

Oxy	B
-	O
induced	O
insulin	B
release	O
was	O
not	O
altered	O
by	O
pretreatment	O
with	O
pertussis	O
toxin	O
(	O
PT	O
)	O

U-73122	O
at	O
8	O
mumol	O
.	O
L-1	O
totally	O
abolished	O
the	O
Oxy	B
-	O
induced	O
increases	O
in	O
[	O
Ca2+	O
]	O
i	O
and	O
IP3	O
;	O
however	O
it	O
reduced	O
the	O
Oxy	B
-	O
induced	O
increase	O
in	O
insulin	B
release	O
only	O
by	O
36	O
%	O
and	O
63	O
%	O
in	O
the	O
monolayer	O
and	O
suspended	O
cell	O
preparations	O
,	O
respectively	O

CONCLUSION	O
:	O
Oxy	B
increases	O
insulin	B
release	O
through	O
both	O
PLC	O
and	O
non	O
-	O
PLC	O
mediated	O
signal	O
transduction	O
mechanisms	O

Further	O
investigation	O
suggested	O
that	O
activation	O
of	O
protein	B
kinase	I
C	I
(	O
PKC	O
)	O
,	O
which	O
is	O
part	O
of	O
the	O
AVP	B
-	O
induced	O
intracellular	O
signalling	O
pathway	O
,	O
is	O
necessary	O
and	O
sufficient	O
for	O
the	O
generation	O
of	O
the	O
synergistic	O
response	O
,	O
although	O
it	O
is	O
not	O
obligatory	O
for	O
AVP	B
-	O
induced	O
ACTH	O
release	O

Oxytocin	B
(	O
OT	O
)	O
is	O
more	O
expressed	O
in	O
the	O
TEC	O
/	O
TNC	O
than	O
vasopressin	O
(	O
VP	O
)	O
;	O
insulin	O
-	O
like	O
growth	O
factor	O
2	O
(	O
IGF-2	O
)	O
thymic	O
expression	O
predominates	O
over	O
IGF-1	O
,	O
and	O
much	O
more	O
over	O
(	B
pro	I
)	I
insulin	I

Thus	O
,	O
OT	B
was	O
proposed	O
to	O
be	O
the	O
self	O
antigen	O
of	O
the	O
neurohypophysial	O
family	O
,	O
and	O
IGF-2	O
the	O
self	O
antigen	O
precursor	O
of	O
the	O
insulin	B
family	O

Downregulation	O
of	O
uncoupling	B
protein	I
2	I
mRNA	O
in	O
white	O
adipose	O
tissue	O
and	O
uncoupling	B
protein	I
3	I
mRNA	O
in	O
skeletal	O
muscle	O
during	O
the	O
early	O
stages	O
of	O
leptin	B
treatment	O

Leptin	B
by	O
intravenous	O
or	O
intracerebroventricular	O
infusion	O
for	O
5	O
h	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
UCP-2	B
mRNA	O
in	O
WAT	O
(	O
47	O
-	O
52	O
%	O
)	O
and	O
UCP-3	B
mRNA	O
in	O
SM	O
(	O
33	O
-	O
37	O
%	O
)	O

Denervation	O
suppressed	O
mRNA	O
levels	O
for	O
UCP-2	B
(	O
49	O
%	O
)	O
,	O
UCP-3	B
(	O
36	O
%	O
)	O
,	O
and	O
COX	O
-	O
IV	O
(	O
59	O
%	O
)	O
and	O
eliminated	O
the	O
acute	O
response	O
to	O
leptin	B
in	O
SM	O

The	O
specific	O
protein	B
kinase	I
C	I
(	O
PKC	O
)	O
inhibitor	O
chelerythrine	O
(	O
5	O
micrometers	O
)	O
inhibited	O
PTH-	O
,	O
AVP-	B
,	O
PGE2-	O
,	O
and	O
adenosine	O
-	O
stimulated	O
Ca2	O
+	O
reabsorption	O
by	O
77	O
%	O
,	O
67	O
%	O
,	O
79	O
%	O
,	O
and	O
100	O
%	O
,	O
respectively	O

CONCLUSION	O
:	O
PTH	O
,	O
AVP	B
,	O
PGE2	O
,	O
and	O
adenosine	O
stimulate	O
Ca2	O
+	O
reabsorption	O
via	O
a	O
pathway	O
that	O
is	O
independent	O
of	O
cAMP	O
and	O
that	O
involves	O
a	O
phorbol	O
ester	O
-	O
insensitive	O
PKC	B
isotype	O

We	O
observed	O
that	O
primary	O
microglial	O
cultures	O
and	O
the	O
THP-1	O
monocytic	O
cell	O
line	O
are	O
stimulated	O
by	O
fibrillar	O
beta	O
-	O
amyloid	O
and	O
prion	B
peptides	O
to	O
activate	O
identical	O
tyrosine	B
kinase	I
-	O
dependent	O
inflammatory	O
signal	O
transduction	O
cascades	O

Enhanced	O
phosphoinositide	O
hydrolysis	O
via	O
overexpression	O
of	O
phospholipase	B
C	I
beta1	O
or	O
delta1	O
inhibits	O
stimulus	O
-	O
induced	O
insulin	B
release	O
in	O
insulinoma	O
MIN6	O
cells	O
.	O

To	O
study	O
the	O
effects	O
of	O
enhanced	O
phosphoinositide	O
hydrolysis	O
on	O
insulin	B
secretion	O
,	O
phosphoinositide	O
-	O
specific	O
phospholipase	B
Cbeta1	I
(	O
PLCbeta1	O
)	O
or	O
PLCdelta1	B
was	O
overexpressed	O
in	O
insulinoma	O
MIN6	O
cells	O
via	O
adenoviral	O
vectors	O
.	O

